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Dedicated to my beloved family! 
 
‘I think, at a child's birth, if a mother could ask a fairy godmother to endow it with the most 
useful gift, that gift would be curiosity.’ 
― Eleanor Roosevelt  
 
 
  
ABSTRACT 
 
The complex and peculiar cell wall architecture is vital for the survival of M. tuberculosis 
in the host and therefore an established target for several currently used drugs. 
Understanding of the cell wall maintenance and the underlying biochemical mechanisms in 
this pathogen is expected to aid the development and evaluation of novel anti-TB therapies. 
Within the scope of this thesis peptidoglycan remodeling enzymes including the essential 
transpeptidase LdtMt2, an NlpC/P60 hydrolase, RipA and a non-catalytic NlpC/P60 variant, 
RipD were investigated.  
LdtMt2, essential in M. tuberculosis for intra-host survival, forms the prevalent 3-3 cross-
links within the cell wall peptidoglycan. The structure of LdtMt2 was solved, a model of the 
three-domain protein located in the periplasm was proposed and the covalent adduct 
formation with β-lactam antibiotics was observed. The systematic analysis of several β-
lactams identified faropenem displaying the fastest binding kinetics and resulting in the 
formation of a stable adduct. These results and the high-resolution structure of LdtMt2 with 
this adduct representing the inactivated state describes the detailed action of faropenem, 
which is the most efficient β-lactam in killing M. tuberculosis in vitro and inside 
macrophages. 
During mycobacterial cell division, daughter cell separation requires endopeptidases from 
the NlpC/P60 protein family. RipD the first non-catalytic member from this family that 
retains PG binding activity and carries a long penta-peptide repeat sequence in C-terminal 
position was characterized. RipA comprises a well-characterized C-terminal endopeptidase 
domain of the NlpC/P60-type and an N-terminal domain of unknown function. The N-
terminal domain was previously implicated in inhibition of the catalytic activity by 
blocking the C-terminal domain. Here we show that it is not the N-terminal domain but the 
lid-module of the inter-domain linker that limits the active site access. The structure of the 
N-terminal domain was solved by X-ray crystallography revealing an elongated domain 
built by two long α-helices. Small angle X-ray scattering in combination with the X-ray 
structures of the two individual domains was used to model the periplasmic RipA protein 
suggesting a rigid, hairpin-like N-module connected to the catalytic domain by a flexible 
linker. This domain organization allows for a defined range of movement of the catalytic 
domain implicated the spatially controlled cell wall degradation. 
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INTRODUCTION 
 
1. TUBERCULOSIS – A GLOBAL CHALLENGE 
Mycobacterium tuberculosis (Mtb) the causative agent of the chronic infectious disease 
tuberculosis (TB) is a highly efficient pathogen. In 2015 about 10 million new TB cases were 
estimated world wide and 60% of the new cases account for six countries: India, Indonesia, 
China, Nigeria, Pakistan and South Africa. The number of multi-drug resistant TB (MDR-
TB) represents about 3.3% of the new cases (Figure 1). In 2015 about 580,000 people were 
newly eligible for MDR-TB treatment but only 20% were enrolled. The crisis of MDR-TB 
detection and treatment is particularly problematic in the five countries that accounted for 
more than 60% of the resulting gap: India, China, the Russian Federation, Indonesia and 
Nigeria. A bit more than half of notified TB patients had a documented human 
immunodeficiency virus (HIV) test result. 78% of patients diagnosed with the ‘HIV-TB 
syndemic’ are enrolled to antiretroviral therapy (ART), which is significantly higher 
compared to MDR-TB patients (WHO report 2016).  
 
Figure 1. Wold Map and New MDR-TB Cases in Percentage (adapted from WHO report 2015). 
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To decrease resistance numbers surveillance is essential and provides indicators whether 
common treatment is effective. The Global Project on Anti-TB Drug Resistance Surveillance 
is the oldest and largest project on surveillance of anti-microbial resistance in the world. 
Recent innovations in molecular diagnostics are facilitating the shift from periodic surveys to 
routine surveillance. For example, rapid molecular tests such as Xpert® MTB/RIF for 
detection of Mtb and rifampicin resistance, provide results much faster than conventional 
methods, do not require sophisticated laboratory infrastructure and decrease cost. 
Currently about 1/4 of world's population, besides patients with acute TB, are latently 
infected, carry a great potential for spreading the disease and developing resistant strains 
(Houben & Dodd 2016). Risk factors such as malnutrition, smoking or substantial alcohol 
abuse and social and economic problems are cause for increased infection risk and early 
disease onset in latent TB infection (Ai et al. 2016, Narasimhan et al. 2013). 
The challenges nowadays to fight the pathogen and the resulting disease TB are global, 
therefore the control and cure strategies have to be orchestrated (Figure 2). Various 
political, social and economic factors play an important role in causation and control of TB. 
National and international prevention and education programs have to be improved e.g. 
with holistic strategies adapted to individual needs (Udwadia & Pinto 2007). Financial 
support and political commitment is essential for research and development (R&D) and for 
developing new application methods and technologies. R&D gives us deep insight into the 
biology of host and pathogen interactions. Understanding molecular mechanisms 
underlying the infection, disease and resistance are crucial to halter the disease and to up- 
and downstream network with R&D to find cure and preventions.  
However, more detailed knowledge about resistance, disease and biology of Mtb is needed 
and application of novel technologies in diagnosis, treatment and prevention. All challenges 
have to be accepted and worked out on national and international levels to reach the WHO 
goal to eliminate TB by 2050 as a public health problem (WHO 2014, Dye & Williams 
2008).  
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Figure 2. The Global TB Challenges Summarized in Categories.  
 
1.1 THE DISCOVERY OF MYCOBACTERIUM TUBERCULOSIS 
Mtb is a pathogen without environmental reservoir and humans are the only known host 
where Mycobacterium tuberculosis and Mycobacterium africanum can maintain infection 
cycles and transmission (Smith et al. 2006).  
The Mycobacterium genus might have originated about 150 million years ago (Hayman 
1984). Mycobacterium tuberculosis (Mtb) sensu-stricto and seven other human-adapted 
mycobacterial lineages that diverged in different regions of the world, have emerged from a 
common ancestor and are classified by 99.9% DNA identity as the Mycobacterium 
tuberculosis complex (MTBC) (Brosch et al. 2002, Supply et al. 2013, Brites & Gagneux 
2015). So far the oldest reported human case of infection with Mtb is dated back 9,000 years 
from a Neolithic Settlement in the Eastern Mediterranean (Hershkovitz et al. 2008). 
Throughout all periods of human history TB was a present threat and reached all continents 
of the world. 
During the 18
th
 and 19
th
 century it reached epidemic levels in Europe and North America 
(Daniel 2006). In 1882, Hermann Heinrich Robert Koch changed the history of tuberculosis 
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with his presentation Die Aetiologie der Tuberculose to the Berlin Physiological Society 
where he also formulated the Koch-Henle postulates and was awarded the Noble Prize in 
Medicine or Physiology in 1905 (Koch 1932). Based on Koch’s findings in 1907 the Austrian 
pediatrician Clemens Freiherr von Pirquet developed the tuberculin skin test and used it to 
demonstrate latent tuberculous infection in asymptomatic children (von Pirquet 1907). In 
1921 Albert Calmette and Camille Guérin developed a ‘Bacille Calmette-Guérin’ (BCG) 
vaccine based on the attenuated laboratory strain of Mycobacterium bovis (Sakula 1983, 
Daniel 2005). After the Second World War, the BCG vaccine was used in the first 
international disease control program (International Tuberculosis Campaign) by the WHO 
based on tuberculin testing followed by BCG vaccination with 30 million tested and 14 
million vaccinated in the period between 1948-1951 (Comstock 1994). Together with the 
discovery of streptomycin in 1944, isoniazid in 1952 and rifamycins in 1957 and their 
antibacterial activity against Mtb, a new era of tuberculosis treatment began (Schatz et al. 
1944, Daniel 2006). Mtb has the ability to rapidly adapt, resist and develop mechanisms to 
counteract drugs and treatment. This limits the lifespan of currently used anti-mycobacterial 
agents and the development of new drugs is of outmost importance. 
 
1.2 THE DISEASE TUBERCULOSIS (TB) - ACTIVE AND LATENT TB 
INFECTION 
Mycobacterium tuberculosis is most commonly transmitted by small infectious droplet 
nuclei of a person with acute TB and can be inhaled reaching the lung alveoli. One cough 
or five minutes of talking can produce enough droplet for successful infection and the 
bacilli may remain airborne for a 30 minutes long period (Loudon & Roberts 1967).   
Encountering Mtb can result in three possible outcomes. In about 10% of the cases a person 
(most common in children or immuno-compromised individuals) will develop primary 
‘active’ TB (Young et al. 2009). Most commonly the lungs are affected resulting in active 
pulmonary TB and symptoms like heavy coughing with cloudy or bloody sputum, fever and 
night sweats, fatigue, weight loss, short breathe and chest pain are well known indicators. 
However the majority, about 90% of patients, infected with Mtb will develop a contained 
form of TB with no disease symptoms referred to as a latent tuberculosis infection (LTBI) 
where bacilli reside in the human lungs over decades causing no active disease. In 10-20% 
of a LTBI patient’s lifetime the infection can be reactivated to active TB (‘post-primary’ 
TB, Lillebaek et al. 2002). Disease onset is supported by an immuno-compromised state 
like HIV infection, diabetes, cancer or drug abuse (Ai et al. 2016). The mechanisms of Mtb 
  5 
transition between latency and reactivation of the disease, the dynamic equilibrium between 
the human-pathogen crosstalk, which triggers the one or other disease outcome, are still 
poorly understood (Kondratieva et al. 2014).  
 
1.2.1 The Human Immune Response and Host-Pathogen Interactions 
Once Mtb is inhaled and on its way to be transported to the alveoli of the lungs it will pass 
through the human first-line innate defence mechanism – the respiratory mucosa (Figure 3, 
Middleton et al. 2002). Here Mtb encounters the epithelium, a layer of airway epithelial cells 
(AECs) the lamina propria, a layer of connective tissue and immune cells with lymphocytes 
and macrophages and a thick mucus layer of airway surface liquid (ASL) (Lugton 1999). 
AECs present receptors also known as pattern recognition receptors (PRRs). The PRRs 
include for example Toll-like receptors (TLRs), Dectin-1, C-type lectin receptors (CLRs), 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2), dendritic cell (DC) 
and mannose receptors to name just a few (Li et al. 2012). PRRs recognise foreign microbial 
components, often macromolecules also known as pathogen-associated molecular patterns 
(PAMPs) that are expressed by Mtb (Akira et al. 2001). After PAMPs have been recognized 
by AECs a first immune response is mounted over presenting antigens to mucosal‐associated 
invariant T cells which triggers the production of cytokines and effector molecules like 
interferon (IFN)-, tumour necrosis factor (TNF)- and granzyme and as a result the onset of 
macrophages to initiate a first response to clear the bacterial infection (Harriff et al. 2014, 
Gold et al. 2010).  
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1.2.1.1 Host-pathogen Interactions in the Alveoli 
 
In case Mtb surpasses the upper airways and reach the alveoli, the bacteria will be exposed to 
type I and type II alveolar epithelial cells (AECs), alveolar macrophages (AMs), dentritic 
cells (DCs) and neutrophils as present defenders (Lerner et al. 2015, Figure 3). Mtb invades 
and replicates in both macrophages and epithelial cells, where the latter plays an important 
role in dissemination of Mtb by undergoing necrosis (Li et al. 2012). Type II AECs secret 
enzymes and hydrolases, together with collectins (e.g. surfactant proteins Sp-A, Sp-D, 
Kishore et al. 2006) produced in the distal lung airspaces bind Mtb and enhance phagocytosis 
(Ferguson et al. 1999, Gaynor et al. 1995). Upon phagocytosis the activation of TLRs triggers 
the recruitment of neutrophils (NP), natural killer (NK) cells and T-cells that are part of the 
early defence against infection (Guirado & Schlesinger 2013). Apoptotic macrophages are 
phagocytised by DCs, which detect PAMPs and present antigens over Major 
Histocompatibility Complex class I and II (MHC I and MHC II) to T-cells in the local 
draining lymph node. This induces the transition from naïve T-cells to effector T-cells 
forming the link between innate and adaptive immune response (Espinosa-Cueto et al. 2017). 
In immuno-competent patients the infection will be contained by the formation of granuloma 
without eradicating Mtb completely leading to LTBI infection (Allen et al. 2015). 
 
Figure 3. Mtb Infection Mechanism in the Human Alveolus.  
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1.2.1.2 Colonization of Macrophages  
 
Phagocytosis by the alveolar macrophage (AM) can occur via different PRRs (Fc receptor, 
mannose receptor, complement receptors e.g. CR3) and receptor molecules expressed on the 
complex Mtb cell surface (Hossain & Norazmi 2013). The fate of Mtb is dependent on which 
receptor system for uptake is used. For example phagocytosis over the Fc receptor results in 
respiratory burst and an inflammatory response where CR3 receptor uptake, dependent on 
cholesterol presence, prevents lysosome-phagosome fusion and prevents activation of the 
macrophage (Pieters 2008, Greenberg 1999, Gatfield & Pieters 2000, Peyron 2000, Ernst 
1998, Brennan & Nikaido 1995).  
Within the AM, Mtb has to counteract harsh environmental conditions like low pH, nutrient 
starvation, hypoxia, reactive oxygen (ROS) and nitrogen species (RNS) (Schnappinger et al. 
2003, Gengenbacher & Kaufmann 2012, Martin et al. 2016). As a response the bacilli have to 
align their metabolism to the environmental changes. The robust impermeable mycobacterial 
cell envelope is the first shield against any threat from the host. The up-regulation of genes 
involved in lipid metabolism is crucial (Chang et al. 2009, Nesbitt et al. 2010). 
Reprogramming mechanisms interfere with the lipid-mediated signalling processes and 
virulence factors like glycolipid lipoarabinomannan (LAM) and phosphatidylinositol 
mannoside (PIM) are coordinating the block in Ca
2+
 fluxes that inhibit phagosomal 
maturation (Rojas et al. 2000, Fratti et al. 2001) and uptake of nutrients by activating a Rab-
dependent pathway (Vergne et al. 2004), respectively. Another survival mechanism of Mtb is 
to arrest the process of phagosome acidification by proton pumps to pH 5.0 and keeping a 
higher pH at pH 6.4 (Gengenbacher & Kaufmann 2012, Sturgill-Koszycki et al. 1994). In the 
phagolysosome, Mtb experiences cationic antimicrobial peptides (CAMPs) e.g. cathelicidin, 
hepcidin and ubiquitin-related peptides, and the robust cell envelope successfully provides a 
physical barrier against it (Flannagan et al. 2009b).  
The remarkable mycobacterial cell envelope and unique lipid and glycolipid composition 
play a vital role in immune recognition and processing Mtb as an infectious agent (Brennan & 
Nikaido 1995). It represents a solid physical barrier for defence and loss of cell wall 
components is correlated with reduced virulence thus playing an important role in immune 
evasion and intracellular survival (Makinoshima & Glickman 2005). 
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1.2.1.3 Granuloma Formation and Containment  
 
The granuloma is the histologically defined object that became the hallmark of tuberculosis. 
By successfully containing the bacilli it also provides Mtb a niche to create a 
microenvironment to survive over long periods. Most important factors for establishment of a 
granuloma and control bacterial proliferation is a balance between the cytokines IFN- and 
TNF- which promote granuloma formation and IL-10 which is a negative regulator (Figure 
3&4, Cooper et al. 2011, Jo et al. 2007).  
Besides the mentioned pro-inflammatory cytokines a complex network of other chemokines 
and cytokines are involved in cell recruitment mechanisms (CC and CXC chemokines) and 
maintenance (Miranda et al. 2012). In general there are three different types of granuloma: a) 
solid granuloma that are formed in LTBI, b) necrotic granuloma, which are typical for active 
TB infection and c) caseous granuloma, which are specific for severe or end-stage TB 
(Gengenbacher & Kaufmann 2012).  
A usual granuloma has spherical shape and consists of blood-derived macrophages (M), 
epithelioid cells (differentiated M) and multinucleated giant cells (Langhans giant cells), 
surrounded by lymphocytes, usually CD4
+
, CD8
+, and γ/δ T-cells (Figure 4). Very typical for 
TB is the appearance of a necrotic centre within the granuloma, also called caseum due to the 
cheese-like appearance. Caseous granulomas are formed by foamy macrophages, epithelioid 
cells and Langhans giant cells and occasionally NK cells, DCs and neutrophils. Surrounding 
the necrotic region is a rim of T- and B-cells (Figure 4, Saunders & Cooper 2000, Toossi & 
Ellner 2001). Other types of granuloma include the solid, non-cavitating, closed granulomas 
containing a central necrotic area that is fully acellular. Importantly granulomas are 
heterogeneous, dynamic structures that contain immune cells and viable Mtb in various 
metabolic stages. The downshift from actively dividing to metabolically dormant Mtb is 
proposed to be triggered by the unfavourable conditions (e.g. nutrient and oxygen starvation) 
inside the granuloma. The DosS/DosT-DosR regulatory complex serves as an important 
biosensor system and is supposed to govern Mtb survival based on NO, CO and oxygen 
availability and the shift from aerobic to anaerobic metabolism (Boon & Dick 2002, Voskuil 
et al. 2011, Sivaramakrishnan & Ortiz de Montellano 2013). 
Processes involved in the equilibrium between LTBI and replicating Mtb remains speculative 
however an attractive model is that dormant Mtb get resuscitated under favourable 
environmental conditions. Resuscitating-promoting factors (Rpfs) are expected to play a role 
in the reactivation process (Gengenbacher & Kaufmann 2012). 
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Figure 4. Structural Organization of Different Granuloma Types.  
 
 
1.3 DIAGNOSIS AND TREATMENT - ACTIVE TB, LTBI AND EMERGING 
DRUG-RESISTANCE 
The diagnosis of active TB is based on the usual symptoms (cough, haemoptysis, fever, night 
sweats, weight loss, chest pain, shortness of breath and fatigue) a Mantoux tuberculin skin 
test (TST) or TB blood test, chest radiography and testing for presence of acid-fast-bacilli 
(AFB) in the sputum. The WHO recommends fixed-dose combination (FDCs) anti-TB 
therapy as the standard regimen for drug-susceptible TB. It includes an intensive phase 
treatment for 2 month with isoniazid, rifampicin, pyrazinamide, ethambutanol
1
 and 
streptomycine
2 
followed by a continuation phase with 4 months of isoniazid and rifampicin, 
all on a daily dose frequency if applicable (WHO 2010, Table 1). 
To monitor the development of multi-drug resistant TB (MDR-TB), which represents TB 
infection resistant to at least isoniazid and rifampicin, a drug susceptibility testing (DST), is 
carried out routinely, adaption of treatment is made if necessary and case control is started 
(WHO 2008). A rare type of MDR-TB is extensively drug-resistant TB (XDR-TB), which 
                                                 
1 
WHO no longer recommends ethambutanol in case of non-cavitary, smear negative TB and HIV-negative 
patients 
2
 Tuberculosis meningitis patients use streptomycine instead ethambutanol 
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shows resistance to isoniazid and rifampicin, and any fluoroquinolone and at least one of 
three injectable second-line drugs. Treatment regimens against MDR and XDR-TB are 
recommended by the WHO and especially for XDR-TB cases have to be designed with great 
care for each individual patient (WHO 2014, Treatment strategies for MDR-TB and XDR-
TB, Table 1).  
If a patient from a risk group shows no typical TB symptoms a TST or interferon-gamma 
release assays (IGRA) indicates that the patient might have developed a LTBI. In case of a 
positive test result, chest radiography follows to screen for abnormalities. Are there chest 
abnormalities visible active TB treatment is performed; in case abnormalities are absent the 
patient receives LTBI adapted treatment. LTBI treatment is recommended with several 
optional methods: 6-month isoniazid, or 9-month isoniazid, or 3-month regimen of weekly 
rifapentine plus isoniazid, or 3–4 months isoniazid plus rifampicin, or 3–4 months rifampicin 
alone. The available LTBI treatment regimens show high efficacy ranging from 60-90% 
(WHO 2015, Guidelines on the management of latent tuberculosis infection). However also 
LTBI patients run a high risk in developing MDR-TB.  
Drug resistance is one of the major problems in the fight against TB. In 2016 about half a 
million of new rifampicin-resistant TB (RR-TB) cases or MDR-TB emerged (WHO 2016). 
To understand the molecular mechanisms causing resistance, for example efflux or hydrolysis 
of drugs, drug modification (phosphorylation, acetylation, glycosylation etc.), reprogramming 
bacterial pathways or hitting off-targets (Davies & Davies 2010) and to find new essential 
targets is necessary to develop new anti-TB drugs with better efficacy. 
 
1.3.1 The Mycobacterial Cell Wall As Target for Antibiotics  
Current TB drugs target the mycobacterial cell on the level of RNA-synthesis (rifapentine), 
DNA-gyrase (fluoroquinilones), protein-synthesis (thioamide, cyclic peptides, 
aminoglycoside) or energy/ATP production (diarylquinoline). However most commonly 
whether it is first-line medication or especially second-line treatment against MDR-TB, the 
mycobacterial cell envelope is the prime target (Table 1). One of the first examples is 
rifampicin, which we today know, besides RNA polymerase inhibition primarily targets 
mycolic acid synthesis (Wehrli 1983, Campbell et al. 2001, Slayden et al. 2000). Mycolic 
acid cyclopropanation is important for the persistence of Mtb in mice (Barkan et al. 2012). A 
plethora of novel inhibitors target the cell wall or biosynthesis pathways of cell wall 
components (Table 1). An example is the synergistic in vitro effects in Mtb of the 
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benzothiazione BTZ043 and ethylenediamide, SQ-109, where the former targets arabinan 
biosynthesis (target: DprE1) and the latter inhibits mycolic acid incorporation (target: 
MmpL3), these are used together with bedaquiline an inhibitor of the respiratory ATP-
synthase (Lechartier et al. 2012, Tahlan et al. 2012, Reddy et al. 2010). 
 
Table 1. Current TB drugs and their Mechanisms of Action (MOA). Drugs targeting cell wall 
synthesis are shaded in grey (table adapted from figures of the NIAID). 
 
 
Isoniazid resistance is often caused by the mutation in the promotor region of inhA and results 
in overexpression of the protein (Basso et al. 1998). New inhibitors against enoyl-reductase 
InhA, a clinically validated target involved in fatty acid biosynthesis and mycolic acid 
synthesis are available. Novel molecules like 4-hydroxy-2-pyridones when used in 
combination with isoniazid and rifampicin against MDR-TB, show a great potential and these 
target the cell envelope (Manjunatha et al. 2015).  
Within the mycobacterial cell envelope peptidoglycan (PG) synthesis has recently gained 
interest as a promising target (Jackson et al. 2013). Cycloserine, inhibiting D-alanine ligase of 
1
st 
Line
Drug
Susceptible 
TB
MDR-TB 
2
nd 
Line 
Treatment
XDR-TB 
Options 
Name Orally/Injection Key Key Key
Isoniazid O E R Targets Mycolic Acids
Rifampicin O E R Inhibits RNA Polymerase
Ethambutanol O E E PE Inhibits Cell Wall Synthesis
Pyrazinamide O E E PE
Target Unclear 
Disrupts Plasma Membrane 
Streptomycin I E** E PE Inhibits Protein Synthesis
Thioamides 
(Ethionamide, Prothionamide) 
O E PE Inhibit Cell Wall Synthesis
Diarylquinoline 
(Bedaquiline TMC-207)
O E E, new Inhibit ATP Synthase
Cyclic Peptides (Capreomycin) I E Inhibit Protein Synthesis
Nitroimidazole 
(Delamanid OPC-67683)
O E E, new Targets Mycolic Acids
Aminoglycosides 
(Kanamycin, Amikacin)
I E inhibits Protein Synthesis
Cycloserine O E PE Inhibit Cell Wall Synthesis
Fluoroquinilones (Moxifloxacin, 
Levofloxacin, Ofloxacin)
O E PE Inhibits DNA Gyrase
Para-aminosolicylic acid (PAS) O E
Inhibit Cell Wall Synthesis and 
Folic Acid Synthesis
Clofazimine O PE Disrupts DNA Template Function 
Name Orally/Injection DS-TB MDR-TB XDR-TB Action
Ethylenediamide SQ-109* O Inhibits Cell Wall Synthesis
Meropenem*(together with clavulanate) I Inhibits PG Synthesis
Imidazopyridine Amide (Q203) O
Inhibits Cytochrome Oxidase
& ATP synthesis
Benzothiazinone (PBTZ169, BTZ043) O Inhibit Cell Wall Synthesis
Oxazolidinones (Sutezolid*, Linezolid*) O Inhibit Protein Synthesis
Rifapentine O Inhibit RNA Synthesis
Macrolides O Inhibit Protein Synthesis
Nitroimidazoles (PA-824*) O Inhibits Mycolic Acids and Others
New Candidate TB Drugs in Development
* Development supported by NIAID
** Used in tuberculosis meningitis
PE … Potentially Effective
E … Effective 
R … Restistant
PE
Action
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the PG peptide chain synthesis (Prosser and de Carvalho 2013), has been long used as a 
second-line treatment and now also to treat MDR-TB. The importance of targeting the PG 
metabolism can be underlined by the efficacy of β-lactam-(meropenem or ertapenem)β-
lactamase (clavulanate) combinations against replicating and persistent Mtb (Hugonnet et al. 
2009, Tiberi et al. 2016). Current work on this strategy show promising efficacy against TB 
and MDR-TB (Hugonnet et al. 2009, England et al. 2012, Dauby et al. 2011, De Lorenzo et 
al. 2013, Payen et al. 2012) and introduction into standard TB chemotherapy is considered 
(Jackson et al. 2013).  
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1.4 THE MYCOBACTERIAL CELL ENVELOPE  
The genus Mycobacterium shares its evolutionary origin with Corynebacterium and Nocardia 
within the Actinobacteria phyla, categorized as gram-positive bacteria with high GC-content 
in their genomic DNA, however the cell wall structure is rather different.  
The complex cell envelope present in Mtb, a distinctive feature of the Mycobacterium genus 
is composed of multiple layers (Figure 5). This peculiar structure and the constituents are 
important for the remarkable resistance to environmental stress and low permeability. 
Extremely long chain fatty acids, so called mycolic acids (MA) and extractable lipids produce 
an exceptionally thick asymmetric bilayer that is serving as the outer membrane (Figure 5, 
Brennan & Nikaido 1995). The mycolic acids are covalently linked to arabinogalactan (AG) 
and that to the innermost peptidoglycan (PG) layer defining the three major sections of the 
mycobacterial cell wall (Figure 5, Kieser & Rubin 2014). These three main components 
within the cell envelope referred to as the cell wall core – the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex – essential for Mtb viability (Alderwick et al. 2015). In 
between the two membranes a controlled environment, similar to the periplasmic space of 
gram-negative bacteria (Daniels et al. 2010) is taking place where the AG and the PG layers 
are situated (Figure 5). 
Nutrients taken up from the surrounding (media or host cell) are passing through porins and 
channels that ensure a controlled communication with the extracellular space. Since the cell 
envelope is a protective shield it is also the target of several antibiotics (Table 1, Sarathy et al. 
2012). Therefore understanding the cell wall structure, biosynthesis and remodelling are 
important for the development of future anti-TB therapies. Additionally, classical cell wall 
components as PG, but also the specific constituents of the mycobacterial cell wall (AG, 
LAM and LM) are involved in the interaction with the host immune system (Barka et al. 
2016). 
In the following the mycobacterial cell envelope layers (Figure 5) are described starting from 
the outermost layer. 
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Figure 5. The Mtb Cell Envelope. (Top panel) Cell envelope architecture is depicted for gram-
positive, gram-negative and mycobacteria. (Bottom panel) An overview of the mycobacterial cell 
envelope layers is illustrated. The inner membrane (IM) with its most abundant phospholipids 
phosphatidylinositol (PI), phosphatidylethanolamine (PE), diphosphatidylglycerol (DPG) and the 
phosphatidylinositol mannosides (PIMs) are represented. Lipoarabinomannan (LAM) and 
lipomannan (LM) are covalently attached to the IM and mannose units are in pyranose configuration 
(Manp). The PG, arabinogalactan (AG) and mycolic acids (MA) are forming the cell wall core, 
where MAs are contributing to the OM. Within the mycobacterial cell envelope arabinan and 
galactan building blocks are in furanose configuration (Araf and Galf). The AG layer is covalently 
linked to the muramic acid moieties in the PG via a GlcNAc-Rha-linker (α-l-Rhap-(1→3)-α-β-D-
GlcNAc-1-P).  
 
1.4.1 The Outer Membrane (OM)  
Although Mycobacteria exhibit common evolutionary origin with gram-positive bacteria their 
cell wall structure is different and the existence of a membrane like structure surrounding the 
PG-AG cell wall core is well established. Cryo-electron tomography (CET) and cryo-
sectioning on M. bovis BCG cells suggested a bilayer thickness ≥10 nm (Figure 5, 
Niederweis et al. 2010, Hoffmann et al. 2008). The main components are free and cell wall 
bound MAs (70-90 carbon -mycolates) covalently linked to the arabinose termini of the 
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mycolyl-arabinogalactan-peptidoglycan (mAGP) cell wall core, and free lipids distributed 
over the OM like trehalose-based lipooligosaccharides (e.g. diacyl- or pentaacyl trehaloses 
(DATs, PATs), sulfoglycolipids (SGLs)), phenolic glycolipids (e.g. phthiocerol 
dimycocerosates (PDIMs)) and glycopeptidolipids (Minnikin et al. 2015). The OM lipid 
composition was estimated based on reverse micellar solution extraction (RMS) on M. 
smegmatis with mostly anthrone-positive glycopeptidolipids (GPLs), large amounts of 
triacylglycerols (TAGs), diacyl gycerols (DAGs) and unknown non-polar lipids (Bansal-
Mutalik & Nikaido 2014). The Mtb genome also encodes for about 140 OM proteins 
(Niederweis et al. 2010). Due to the high hydrophobicity of the OM, hydrophilic nutrients or 
drugs require transport through channels and porins. Virulence factors and extracellular 
materials for capsule and biofilm formation (glycans and glycogens) are proposed to be 
translocated across the OM, and play a crucial role for intra-host survival and persistence in 
mice (Sambou et al. 2008).  
 
1.4.2 The Inner Membrane (IM) 
The inner membrane (IM), or conventional cytoplasmic membrane of Mtb is mostly 
composed of phospholipids like cardiolipin, phosphatidylinositol (PI), 
phosphatidylethanolamine (PE) and diphosphatidylglycerol (DPG) (Figure 5). The specific 
component is the inositol phosphate esterified lipids not present in other prokaryotic cell 
envelopes (membrane or cell wall) but common in eukaryotes. In mycobacteria most 
commonly four phosphatidylinositol mannosides (PIMs) are present, where most abundant 
are diacyl phosphatidyldimannoside (Ac2PIM2) with about 40 %, mono phosphatidylinositol 
dimannosides (AcPIM2) and mono- and diacyl phosphatidylinositol hexamannoside (AcPIM6 
and Ac2PIM6) (Minnikin et al. 2015, Bansal-Mutalik & Nikaido 2014). The lipoglycans 
lipomannan (LM) and lipoarabinomannan (LAM) are attached to PIMs, over a manno-
phosphatidylinositol (MPI) anchor (Minnikin et al. 2015). The hydrophilic part of lipoglycans 
is most likely protruding into the periplasmic space of the cell wall moreover protruding 
through pores within the mAGP reaching through to the OM (Pitarque et al. 2008). LM and 
LAM are immune-modulatory molecules. Mannose-capped LAM is involved in phagocytosis 
recognized by host C-lectins and phosphoinositol-capped LAM and LM stimulate the innate 
immune system through TLR2s, which requires transport of lipoglycans to the outer 
membrane (Gilleron et al. 2008). Recently, the Mtb lipoprotein LprG was identified to bind 
LAM and controls its distribution in the cell envelope to enhance host interaction (Shukla et 
al. 2014).  
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1.4.3 The Mycolyl-Arabinogalactan-Peptidoglycan (mAGP) Cell Wall Core 
AG is built of arabinose and galactose units, which are in furanose configuration 
(Arabinofuranose: Araf and Galactofuranose: Galf) (McNeil et al. 1987, Brennan and Nikaido 
1995). The first element is a linear chain of around 30 alternating 1→5 and 1→6 linked Galf 
units. Three branched arabinan chains are linked to position C5 of galactan. Each arabinan 
chain is composed of 30 Araf units linked 1→3, 1→5 in 1,2 trans and 1→2 in 1,2 cis manner 
and the non-reducing end is free for mycolic acid, succinyl or galactosamine attachment 
(Alderwick et al. 2015, Abrahams & Besra 2016). Mycolic acids are connected via an ester 
linkage to the arabinose termini (Minnikin et al. 2015). The root of the branching AG is 
connected to the O6 of muramic acid in the peptidoglycan (PG) layer using a mycobacterial 
specific linker (α-l-Rhap-(1→3)-α-β-D-GlcNAc-1-P). About 10% of muramic acid residues 
within the PG layer are connected to AG (McNeil et al. 1987, Barry et al. 2007).  
The PG layer forms a continuous meshwork around the cell, also called the sacculus, and is 
only found in bacterial cells. It is responsible to sustain shape and stability of the cells as well 
as counteracting turgor pressure (Vollmer et al. 2008, Turner et al. 2014). The model 
organisms in which the PG structure and composition was studied primarily are Escherichia 
coli, Bacillus subtilis and Staphylococcus aureus (Turner et al. 2014). In the following the 
general structure of the bacterial cell wall PG is described and the specific alterations found 
in Mtb are discussed.  
The glycan chains of the PG is built by alternating N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) that are connected over (1→4) linkages (Figure 6). In Mtb 
the occurrence of N-glycolyl-muramic (MurNGlyc) acid has been reported (replacing 
MurNAc), which tightens the meshwork (Raymond et al. 2005). Each MurNAc moiety 
carries a short tetra- or penta-peptide stem that form inter-peptide bridges to the peptide stem 
of another glycan chain. The sequence of the peptide stems in mycobacterial PG composition 
is primarily L-Ala-γ-D-Glu-meso-DAP-D-Ala-D-Ala in nascent peptidoglycan where the 
final D-Ala is often removed in the mature PG macromolecule (Vollmer et al. 2008). In Mtb 
the amidation of the carboxylate groups of the meso-DAP and D-Glu residues peptide stems 
account for a specific deviation from the conventional PG structure. Two types of peptide 
cross-links are found in Mtb. The conventional 3-4 peptide cross-link (D-D cross-links) 
formed between the donor peptide on fourth position D-Ala and the meso-diaminopimelic 
acid (m-DAP) on position three of the acceptor peptide stem. And the alternative, so called 3-
3 cross-links formed between m-DAP residues, hence termed DAP-DAP cross-links (L-D 
cross-links) occur in spores and stationery phase in gram-positive organisms. In mycobacteria 
these specific DAP-DAP cross-links (Figure 6) account for about 80% within the PG layer 
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and these are more abundant in dormant bacteria and probably the relevant type of linkages 
during intra-host survival in this pathogen (Kumar et al. 2012, Lavollay et al. 2008). 
Different models have been proposed for the arrangement of the PG strands including parallel 
(Vollmer et al. 2008) or perpendicular (Meroueh et al. 2006) arrangement to the cell 
membrane. The parallel arrangement of glycan strands with the plasma membrane is the 
model supported by more experimental data. The perpendicular arrangement is not 
compatible with the long glycan strands >5 µM present in B. subtilis, however in other gram-
positive bacteria perpendicular PG arrangement might be possible (Turner et al. 2014). 
Establishment of the PG strand arrangement within the sacculus needs further investigation 
by new high resolution imaging technologies or combinatory approaches e.g. fluorescent 
probes in combination with super-resolution imaging techniques (Turner et al. 2014, 
Abrahams & Besra 2016, Minnikin et al. 2015).  
 
1.4.3.1 Peptidoglycan (PG) Synthesis in Mtb 
 
The carbon skeleton for PG synthesis comes from glycolysis where fructose-6-P is converted 
into glucosamine-6-P by the glucosamine-6-phosphate synthase GlmS and 
phosphoglucosamine mutase GlmM to form glucosamine-1-P (GlcN-1-P). The first 
committed step, the formation of the PG building block branch, starts from GlcN-1-P and 
GlmU (acetyltransferase and uridyltransferase activity) using acetyl coenzyme A (acetyl-
CoA), where first the acyl group and as a second step uridine-5’-monophosphate from UTP is 
transferred, to form uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) (Figure 6). In 
the next steps cytoplasmic synthesis of UDP-N-acetylmuramic acid (UDP-MurNAc)-penta-
peptide (also known as Park’s nucleotide), is performed by enzymes of the Mur family 
(MurA-F) that successively incorporate the amino acids L-Ala, D-iso-Glu, m-DAP and D-
alanyl-D-Ala added by the ligase Ddl (Kurosu et al. 2007, Barreteau et al. 2008, Abrahams & 
Besra 2016). The members MurC, MurD, MurE and MurF catalyze ATP-dependent non-
ribosomal peptide bond formation by adding peptide moieties to the PG building block. They 
are essential for mycobacterial survival and represent validated targets for developing new 
anti-mycobacterial drugs (Kouidmi et al. 2014). 
An important step within building up the PG units involves UDP-N-acetylmuramic acid 
hydroxylase, NamH, which modifies a fraction of UDP-MurNAc to UDP-N-glycolylmuramic 
acid (UDP-MurNAc/Glyc) (Mahapatra et al. 2005a, Abrahams & Besra 2016). This 
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modification is unique to mycobacterial cells, decreases lysozyme susceptibility and tightens 
the intrinsic PG strength (Raymond et al. 2005). 
The first membrane anchored PG precursor is generated by MurX, which couples the Park’s 
nucleotide to decaprenyl phosphate (C50-P) forming Lipid I (Kurosu et al. 2007). The last 
intracellular step is the (1→4) linkage between UDP-GlcNAc and MurNAc/Glyc carried out 
by the glycosyltransferase MurG, which results in generation of Lipid II, the monomeric PG 
building block (Mengin-Lecreulx et al. 1991). Two enzymes, MurJ and/or FtsW, are 
suggested to translocate Lipid II across the IM (Ruiz 2015). Recently the structure of MurJ in 
Thermosipho africanus was solved and providing first insights into 
multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) transporter superfamily function and 
translocation of PG-units (Kuk et al. 2017). After translocation the mono or bifunctional 
penicillin-binding-proteins (PBPs) are polymerizing the PG units releasing them from Lipid 
II (Sauvage et al. 2008).  
 
Figure 6. Cytoplasmic Synthesis and Periplasmic Assembly of PG. Key enzymes involved in 
cytosolic and periplasmic PG synthesis.  
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1.4.3.2 PG Polymerization  
 
Mycobacteria possess several PG synthases that polymerize Lipid II and cross-link the 
peptide stems to a multi-layered PG meshwork (Figure 6&7). The most prominent 
polymerizing enzyme group is the PBPs, usually membrane-bound proteins (SxxK D,D-
acyltransferase group I) classified into Class A (glycosyltransferase domain fused to SxxK 
acetlytransferase of class A) and Class B (protein recognition module fused to SxxK 
acetyltransferase of class B). The reason for the name Penicillin Binding Protein (PBP) is that 
their transpeptidase (TP) domain is covalently modified and inhibited by penicillin and 
other-lactam antibiotics (Goffin & Ghuysen 2002). Bifunctional PBPs of Class A, like 
PonA1 and PonA2 (PBP1 and PBP2 in E. coli), carry out transglycosylation (TG domain) 
and transpeptidation (TP domain), for linking the disaccharide building blocks of Lipid II to 
existing glycan chains and catalyze conventional 3-4 peptide cross-links between m-DAP and 
D-Ala of the adjacent penta-peptide chains, with the cleavage of the terminal D-Ala (Figure 
7). Class B PBPs have a TP domain and a non-catalytic domain for enzyme positioning or 
promoting protein-protein interactions. Monofunctional PBPs carry out D,D-transpeptidation 
(TP), D,D-carboxypeptidation (CP) with the release of a D-Ala or can even break 4-3 cross-
links by D,D-endopeptidase activity (EP) (Egan & Vollmer 2015, Goffin & Ghuysen 2002).  
PBPs are the classical targets for the -lactam antibiotics. For a long time the -lactam 
antibiotics were not considered as potential treatment against TB since most of them are 
inactivated by the -lactamase BlaC (Hugonnet & Blanchard 2007). Combination of 
clavulanic acid, which irreversibly inhibits BlaC with carbapenems (imipinem and 
meropenem) however, shows promising results in Mtb-infected macrophages or against 
XDR-TB in vitro (England et al. 2012, Hugonnet et al. 2009). Using -lactams and targeting 
Ldts and the process of the predominant 3-3 cross-link and PG biosynthesis can represent a 
novel strategy in TB therapy (England et al. 2012, Hugonnet et al. 2009, Kumar et al. 2017, 
Steiner et al. 2017). 
However the majority of the peptide cross-links (about 80%) in the Mtb PG are of 3-3 type. 
Their formation includes the release of D-Ala at the fourth position and is carried out by the 
L,D-transpeptidases (Ldts) LdtMt1-LdtMt5 (Figure 7, Kumar et al. 2012). The L,D-
transpeptidases are not related to the D,D-transpeptidases present in PBPs, represent a 
different protein fold and active site architecture. For instance an invariant catalytic cysteine 
residue instead of a serine found in PBPs (Mainardi et al. 2005). 
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Figure 7. (Top panel) PG polymerization processes in Mtb. Lipid II is attached to an existing 
glycan-peptide chain by glycosyltransferase (GT) action and the undecaprenol pyrophosphate anchor 
is released. Inter-peptide stem cross-links are formed by D,D-transpeptidases using the 
transpeptidase domain (TP) catalyzed by PBPs (PonA1 and PonA2) forming conventional 4-3 cross-
links. Some PBPs can hydrolyze the D-Ala of the penta-peptide stem or the 4-3 cross-link through 
D,D-carboxypeptidase (CP) or endopeptidase activity (EP), respectively. The predominant 3-3 
cross-links specific for mycobacteria are catalyzed by the L,D-transpeptidases (Ldts). (Bottom 
panel) The PG growth is illustrated in a simple model involving the necessary enzyme activities 
(EP, GT, TP). The GT activity from class A PBPs is inserting Lipid II (PG precursor) into the 
existing PG network together with the TP activity of class A and class B PBPs. The EP cleaves the 
cross-links within the PG layer to allow insertion of new material in between the existing PG chains 
(figure adapted from Pazos et al. 2017). 
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1.4.3.3 The L,D-Transpeptidases (Ldts) in Mtb 
 
In the Mtb H37Rv genome five homologs of Ldts can be found (Figure 8A) representing 
short (Rv0116c, Rv1433 and Rv0192) and long (Rv2518c and Rv0483) variants reflecting 
the domain organization e.g. two or three domain proteins. The common features of these are 
the catalytic transpeptidase domain in C-terminal position preceded by one or two spacer 
domains of the Ig-fold-type (Böth et al 2013). They are all required for cell wall stability and 
gene knock-out studies showed that each results in alteration of cell size, stability and 
increased susceptibility to -lactam antibiotics (e.g. amoxicillin, imipinem) (Gupta et al. 
2010, Schoonmaker et al. 2014, Sanders et al. 2014).  The overall sequence identity is 
moderate with about 30–35%, where the two paralogs LdtMt2 and LdtMt5 are in closest 
relationship. High sequence conservation can be observed for all Ldts in Mtb when 
comparing the catalytic transpeptidase domain (C) and also suggests the presence of at least 
one N-terminal module (Ig domain) for all homologs (Figure 8A). However, until now 
structural information is only available for three of the five homologs, LdtMt1, LdtMt2 and 
LdtMt5 (Figure 8B) (Correale et al. 2013, Böth et al. 2013, Li et al. 2013, Basta et al. 2015).   
The L,D-transpeptidase-2 (LdtMt2, Rv2518c) in Mtb, responsible for the predominant 3-3 
cross-links during all growth stages in Mtb, was shown to be essential for infectivity in mouse 
model of acute TB infection and exhibits the highest expression level (Gupta et al. 2010). The 
LdtMt2 consists of a catalytic domain with the characteristic ErfK/YbiS/YhnG (EYY) fold and 
two consecutive domains belonging to the immunoglobulin (IgG) fold family (paper I - Böth 
et al. 2013, Erdemli et al. 2012, Kim et al. 2013, Li et al. 2013). Besides the PBPs as the main 
target, the LdtMt2 was shown to be targeted by -lactam antibiotics, primarily by the 
carbapenem-type. The covalent binding of -lactams and inactivation kinetics were 
investigated by biochemical and structural methods (paper I and paper II - Böth et al. 2013, 
Erdemli et al. 2012, Kim et al. 2013, Li et al. 2013, Steiner et al. 2017).  
The paralog of LdtMt2, LdtMt1 (Rv0116c) is an example for the short two-domain variant was 
also found to be inactivated by carbapenems (Correale et al. 2013) and thought to play a 
critical role in peptidoglycan adaptation to the non-replicative state of Mtb (Lavollay et al. 
2008, Dubée et al. 2012). Structural comparison of the two structures shows good overall 
similarity with an r.m.s.d. of 1.5 Å (over all C atoms) (Correale et al. 2013).  
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Figure 8. L,D-transpeptidase (Ldt) Homologs in Mtb H37Rv. (A) Domain arrangement of the 
five Ldt homologs. The conserved catalytic domain (C) with its characteristic ErfK/YbiS/YhnG 
(EYY) fold (red box), the domains belonging to the immunoglobulin (Ig) fold family (brown 
box) and the transmembrane regions (TM, purple box) are represented. The genetic location is 
given as Rv codes in brackets (B) Structural comparison of the three crystal structures available 
for LdtMt1 (PDB: 4JMN), LdtMt2 (PDB: 3VYN) and LdtMt5 (PDB: 4Z7A). Images were made 
using MacPyMol. The Mtb Ldt homologs show different distance of the catalytic active site 
cysteine residues (red sticks) to the IM therefore reaching to different levels (60 Å and 80–100 
Å) in the PG layer. (C) Multiple sequence alignment of LdtMt1-LdtMt5 using Clustal Omega 
(Sievers et al. 2011) and ESPript 3.0 (Robert & Gouet 2014). Strictly conserved residues are 
highlighted with a red box. The active site residues His336, His352 and Cys354 of LdtMt2 are 
highlighted with star and tilde symbols. The B and C domain region of LdtMt2 are indicated with 
a grey and red bar respectively. 
 
1.4.3.4 Cell Wall Growth and Division in Mycobacteria  
 
PG forms a net-like, continuous macromolecule of polymerized glycan strands and cross-
linked peptides, called the sacculus, surrounding the cytoplasmic membrane. A bacterial cell 
needs to increase the surface of its sacculus in order to grow and divide. The sacculus growth 
and division during daughter cell separation is a challenging balance between rebuilding and 
simultaneously degrading PG and has to be well-controlled to avoid accumulation of defects 
within the cell wall causing increased susceptibility to antibiotics and cell lysis (Egan & 
Vollmer 2015). Most studies on cell elongation and division were carried out on Escherichia 
coli and gram-positive Bacillus subtilis, Staphylococcus aureus and Streptococcus 
pneumoniae, demonstrating the arrangement of protein complexes and interactions between 
PG synthases, hydrolases, regulatory proteins, and cytoskeletal elements (Typas et al. 2012, 
Egan & Vollmer 2013). The concept of the divisosome and elongasome was born including 
the above constituents contributing to these large membrane-linked machineries (Egan & 
Vollmer 2015, Kieser & Rubin 2014).  
These multi-protein complexes carry out the cell elongation, septum formation and daughter 
cell separation synchronized with the genome replication and chromosome segregation 
(Szwedziak & Lowe 2013). Both complexes have common features and subunits consisting 
of enzymes required for the incorporation of new subunits into the growing PG sacculus, as 
well as proteins, like Wag31 and FtsZ, acting as scaffold platforms for large cell elongation 
and division complexes (Figure 9, Kieser & Rubin 2014, Favini-Stabile et al. 2013). The 
elongation complex involves the PBPs and PG hydrolases responsible for PG synthesis and 
hydrolysis. The activity of these proteins have to be strictly regulated and are guided to the 
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cell poles by the scaffold protein Wag31, the Mtb homolog of the better investigated DivIVA 
in B. subtilis (Typas et al. 2012, Hett & Rubin 2008, Plocinski et al. 2012). The CrgA–CwsA 
(cell wall synthesis protein A) complex is interacting with Wag31, which is involved in 
peptidoglycan synthesis and cell shape determination (Plocinski et al. 2012). As the PG layer 
is highly cross-linked during all growth stages also Ldts might be recruited to the elongation 
complex, substituting for PBPA (Figure 9, Kieser & Rubin 2014).  
Possible interaction and cross-talk between the elongation machinery and the cell division 
complex might move PG synthesis to the mid-cell. Very specific for mycobacterial cell 
division is asymmetric septation (daughter cell separation). The reason for this is unknown 
but variation in size between daughter cells increases population heterogeneity (Kieser & 
Rubin 2014). After PG degradation the two daughter cells appear as V-shaped object, maybe 
resulting from asymmetric splitting or from unbalanced levels of AG and MA layers that are 
proposed to stay intact during the whole mycobacterial cell separation (Hett & Rubin 2008, 
Kieser & Rubin 2014).  
After septum synthesis is finished daughter cells have to be separated. Daughter cell 
separation is dependent on RipA an NlpC/P60-type endopeptidase enzyme (Gao et al 2006, 
Hett et al. 2007) localized at the septum of dividing cells. Mycobacteria encode for several 
PG hydrolases, where the most prominent candidates are the individually non-essential 
hydrolases RipA and RipB (Martinelli & Pavelka 2016) and RipC (Parthasarathy et al. 2012). 
RipA also interacts with other PG hydrolase, the resuscitation promotion factor B (RpfB) 
containing a lysozyme-like domain. The two enzymes are proposed to synergistically cleave 
peptide and glycoside bonds in the PG (Hett et al. 2007). PonA1 was also found to form a 
complex with RipA probably competing for binding with RpfB (Hett et al. 2010). Here, the 
balance between PonA1-RipA and RpfB-RipA interactions might regulate that synthesis is 
carried out before degradation of the septum (Kieser & Rubin 2014). Another crucial PG 
hydrolase is RipC shown to interact with FtsX and needed for Mtbs full virulence 
(Parthasarathy et al. 2012, Mavrici et al. 2014). 
Septation in E. coli or in S. pneumoniae requires amidases like, AmiA/B/C or LytA 
respectively that cleave the PG in between the MurNac and the peptide stem. In Mtb this 
process was clearly linked to the endopeptidase RipA however, the role of amidases is poorly 
understood in mycobacteria (Priyadarshini et al. 2007, Mellroth et al. 2012). Recently the 
discovery of a N-acetylmuramyl-L-alanine amidase (Rv3717) from Mtb points to a role in 
recycling of degraded PG fragments (Prigozhin et al. 2013).  
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Figure 9. The Elongation and Division Complex in Mycobacteria. The complexes are built up of PG 
synthases (purple), hydrolases (green), scaffold proteins regulating structure (beige), regulatory 
proteins (blue) involved in cell elongation and separation. The elongation complex is anchored by 
Wag31, which itself is stabilized by CwsA. New PG is incorporated by PonA1 produced by cell wall 
hydrolases, which also loosen the structure for insertion of new material. PonA2 together with the 
Ldts are cross-linking and further polymerizing the PG meshwork (left panel). Cell division is 
initiated by polymerization of FtsZ and Z-ring formation is regulated by regulatory proteins e.g. PknA, 
ClpX or Rv3660c. Structural proteins FtsW/Q, CrgA and CwsA are joining to assemble the divisome 
and together with PBPA/B, PonA1 and Ldts form the septal disc. In a dynamic network, the 
hydrolysases RipA and RpfB, a synergy of peptide and glycoside cleavage, facilitated by FtsE and 
FtsX, the daughter cells are separated without losing integrity (right panel, figure adapted from 
Kieser & Rubin 2014). 
 
1.4.3.5 The PG Hydrolases of the Rip Family  
 
PG remodelling at the septum and daughter cell separation in Mtb was found to be dependent 
on the NlpC/P60 domain containing endopeptidase RipA (Anantharaman & Aravind 2003, 
Gao et al. 2006). The Mtb genome encodes for five proteins with such an NlpC/P60 
(NlpC/P60: new lipoprotein C from E. coli and a 60 kDa extracellular protein from Listera 
monocytogenes) domain: Rv0024, RipA (Rv1477), RipB (Rv1478), RipC (Rv2190c) and 
RipD (Rv1566c) (Figure 10). Rv0024 lacks export signal sequence, hence it is likely 
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intracellular but uncharacterized. The catalytic NlpC/P60 hydrolase domain contains a 
catalytic site analogous to the papain-like peptidases (Anantharaman & Aravind 2003) based 
on a cysteine, in the conserved motif ‘DCSG’, a histidine and glutamate (Parthasarathy et al. 
2012). These PG hydrolases contain an additional domain or shorter modules in N-terminal 
position (RipA, RipB, RipC), or C-terminal extensions (RipD) attached to the catalytic 
domain. Loss of either RipA or RipB causes increased susceptibility to antibiotics however 
the mutant phenotype can partially be rescued by RipD (Martinelli & Pavelka 2016).  
RipA is the best characterised member of the Rip-family (Figure 10) and was shown to 
interact with the resuscitation promoting factors RpfB (Rv1009), RpfE (Rv2450c) and with 
PonA1 (Hett et al. 2007, Hett & Rubin 2008). The catalytic activity regarding PG degradation 
has been established for RipA and RipB indicating a pH optimum of 5-6, and the cleavage 
position in between the D-Glu/m-DAP residues. The PG degradation activity and PG binding 
properties were characterized (Böth et al 2011, Ruggiero et al. 2010). The N-terminal module 
of RipA remains unknown, however it was proposed to be an inhibitory module regulating 
the catalytic activity (Ruggiero et al. 2010, Botella et al. 2017). This N-terminal module 
occurring in RipA and RipC shows 35 % sequence identity (RipA residues 39-255, RipC 
residues 38-212). It was proposed to mediate the interactions between RipC and FtsX 
(Mavrici et al. 2014). The structure of this domain was solved by X-ray crystallography and 
the results from small angle X-ray scattering (SAXS) allowed to model the domain-
arrangement of the whole periplasmic part of RipA including the N-terminal domain and the 
catalytic domain (paper IV). 
RipC is expected to carry out similar catalytic activity, as RipA based on sequence homology, 
although otherwise remains uncharacterized. From genetic analysis it appears to be necessary 
for virulence (Parthasarathy et al. 2012).  
RipD represents an exception, a non-catalytic variant of the NlpC/P60 hydrolase family. The 
cysteine (Cys383 in RipA and Cys152 in RipB) of the catalytic triad is replaced by an alanine 
and the histidine (His432 in RipA and His201 in RipB) by a serine residue. Another peculiar 
feature of RipD is the 61 residues long repeat sequence attached to the NlpC/P60 domain in 
C-terminal position containing the PVQQA motif (paper III, Böth et al. 2014). The function 
of RipD is so far unknown but might be involved in protecting PG cleavage sites and/or 
recruiting other cell wall remodelling proteins.  
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Figure 10. The Four Periplasmic NlpC/P60 Hydrolases in Mtb. (A) The Mtb genome encodes for at 
least five homologous NlpC/P60 proteins, where RipA, RipB, RipC and RipD have a predicted 
signal sequence indicating localization into the PG periplasm (TM). RipA and RipB carry an 
additional lid-module covering the catalytic doman labelled with X and Y respectively. RipA and 
RipC also feature an additional N-terminal module (approx. 200 residue-long). In RipD, the 
NlpC/P60 domain is non-catalytic (cross) and carries a 61 residue long PVQQA-repeat at its 
terminus (paper III). (B) Enzymatic activity and cleavage position within the PG layer of RipA and 
RipB hydrolases. Dashed lines indicate the two potential cross-link types present in the PG of Mtb. 
(C) Structure of RipAc (blue, residues 260-472, PDB: 3PBC) and RipB (orange, residues 30-241, 
PDB: 3PBI). The catalytic cysteine of RipA and RipB are highlighted in red.  
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1.4.4 Inhibitors Targeting PG Synthesis in Mtb 
PG is unique to bacterial cells and therefore enzymes involved in metabolism and synthesis 
are targeted by antibacterial compounds but also promising targets for the development of 
novel antibiotics (Table 2). There are few essential proteins in bacterial genomes, and not all 
of these can be used as a target because of close homology to human enzymes. The first 
example at the beginning of PG synthesis is GlmU with acetyltransferase and 
uridyltransferase activity forming UDP-GlcNAc (Figure 6). Due to the close homology of the 
GlmU uridyltransferase domain to human enzymes only the acetyltransferase domain 
represents a potential target and currently inhibitors and substrate analogs of GlcN-1-P are 
under development (Tran et al. 2013, Abrahams & Besra 2016).  
 
Table 2. Inhibition of PG synthesis. 
 
 
The following Mur ligases build up the peptide chain linked onto UDP-MurNAc/Glyc 
(Figure 6). Despite their distinct peptide selectivity Mur C-F ligases share a common ATP 
binding domain, and small molecule inhibitors are identified (Barreteau et al. 2008, Hrast et 
al. 2014, Abrahams & Besra 2016). The next validated target represents, Ddl, which is 
Target Protein Inhibitor Mode of Action
GlmU Substrate analogs of GlcN-1-P Acetyltransferase activity
MurB Dioxopyrazolidines
UDP-N -acetylenolpyruvylglucosamine 
reductase
Ddl D-cycloserine (D-Ala analogue) D-alanine ligase
MurX (MraY)
Natural products e.g. 
muraymycin, liposidomycin,
caprazamycin and capuramycin
SQ641 (preclinical development)
Translocase I
MurG
Ramoplanin 
(lipoglycodepsipeptide)
Transition state mimics
Binding Lipid I and Lipid II 
Preventing MurG action and 
polymerization
Lipid II
Lantibiotics (Nisin)
Ramoplanin
Interaction with pyrophosphate moiety 
D-Ala-D-Ala binding, 
Inhibition of PG polymerization
Moenomycin (natural product 
glycolipid)
-lactams 
Ldts -lactams Transpeptidase activity
PBPs Transglycosylase activity
Pentapeptide stem
Vancomycin, Teicoplanin 
(glycopeptides)
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inhibited by D-cycloserine, acting as D-Ala analogue, currently used against MDR-TB and 
XDR-TB (Prosser & de Carvalho 2013a,b). 
Several nucleoside-based natural products inhibit membrane anchoring of the Lipid I 
precursor by MurX (Table 2, Abrahams & Besra 2016). Capuramycin shows killing of non-
replicating TB in vitro and in vivo, which is not common for most of PG synthesis inhibitors 
(Siricilla et al. 2015). 
Compounds mimicking the transition state during enzyme catalysis targeting MurG from E. 
coli are now tested on Mtb MurG, and successfully inhibited the generation of Lipid II, the 
final intracellular step of PG synthesis (Trunkfield et al. 2010).  
The polymerization of Lipid II in the periplasm is carried out by PBPs (mono- and 
bifunctional) and L,D-transpeptidases (Ldts). The -lactam antibiotics, mainly targeting the 
PBPs, experience a revival as potential anti-TB treatment; particularly the carbapenems class 
show also inhibition against Ldts (paper I - Böth et al. 2013, Erdemli et al. 2012, Kim et al. 
2013, Li et al. 2013, Mainardi et al. 2007, Dubée et al. 2012, Lecoq et al. 2012). Combination 
treatment of -lactams and -lactamase inhibitors against BlaC in Mtb show promising 
efficacy in both non-replicating and active TB and clinical trials are currently ongoing 
(Hugonnet et al. 2009, Rullas et al. 2015). Another class, the penem-type of -lactams 
appeared in the field as faropenem was found to be the most effective even in the absence of 
clavulanic acid against Mtb in culture but also inside macrophages (paper II, Dhar et al. 
2015). Considering the favorable properties of faropenem (stable and oral bioavailability) and 
the above fact it has been proposed as a good candidate for TB chemotherapy (Dhar et al. 
2015, Steiner et al. 2017, Hoagland et al. 2016, WHO 2017 Executive Summary).  
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2 AIMS OF THE THESIS 
 
Paper I and Paper II – ‘Structure of LdtMt2, an L,D-transpeptidase from 
Mycobacterium tuberculosis’ and ‘Binding and processing of β-lactam antibiotics by 
the transpeptidase LdtMt2 from Mycobacterium tuberculosis’. 
 Structural characterization of the essential transpeptidase LdtMt2 using X-ray 
crystallography, give insights to the transpeptidation by the five mycobacterial 
homologues. 
 Comparison of the action of different β-lactam antibiotics using enzyme 
kinetics, mass spectrometry and X-ray crystallography. Analysis of the adducts 
and the events following the acylation reaction. 
 Identification of the most efficient β-lactam compound and explain the 
mechanism of action in detail. 
 
Paper III - RipD (Rv1566c) from Mycobacterium tuberculosis: Adaptation of an 
NlpC/P60 Domain to a Non-catalytic Peptidoglycan-binding Function. 
 Structural investigation of the NlpC/P60 domain of RipD (Rv1566c). 
 Biophysical characterization of the 61-residues long penta-peptide (PVQQA) 
repeat sequence in C-terminal position.  
 
Paper IV - Structure of the N-terminal Module of the Cell Wall Hydrolase RipA and its 
Role in Regulating Catalytic Activity. 
 Structural characterization of the N-terminal module of the NlpC/P60 hydrolase 
RipA using X-ray crystallography and small-angle X-ray scattering (SAXS).  
 Investigation of the role of the N-terminal module and the inter-domain linker 
with regards to active site access. 
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3 RESULTS AND DISCUSSION  
 
3.1 PAPER I: STRUCTURE OF LDTMT2, AN L,D-TRANSPEPTIDASE FROM 
MYCOBACTERIUM TUBERCULOSIS 
The L,D-transpeptidase 2 from Mtb (LtdMt2) catalyzes the formation of the 
predominant 3-3 cross-links within the PG layer and was shown to be essential for 
virulence in Mtb. Among the five homologues within the Mtb genome LtdMt2 is 
expressed at the highest level (Gupta et al. 2010). Inactivation of the LdtMt2 gene lppS 
(rv2518c) led to an attenuated phenotype and to increased susceptibility to 
clavulanate-amoxicillin treatment in vitro and in a mouse TB model (Gupta et al., 
2010). The essentiality of LdtMt2 for virulence makes it a potential target for antibiotic 
development. The targeting of L,D-transpeptidases in Mtb by -lactam antibiotics has 
been exemplified by several examples (paper I and paper II, Dubée et al. 2012, 
Erdemi et al 2012, Böth et al. 2013, Kim et al. 2013, Li et al. 2013, Bianchet et al. 
2017). Promising results were obtained by combination therapy of clavulanic acid and 
carbapenems (imipinem and meropenem) in Mtb-infected macrophages or against 
XDR-TB in vitro. Inhibition of the 3-3 cross-link formation and PG biosynthesis 
represents a promising strategy in anti-TB therapy (England et al. 2012, Hugonnet et al. 
2009, Dhar et al. 2015, Hoagland et al. 2016).  
The gene of LdtMt2 encodes for an enzyme with 408 amino acids. A short intracellular 
segment (residue 1-17), a trans-membrane domain (residue 18-34) and a large 
periplasmic part (residue 35-408) was predicted and potential domain organization for 
the extramembrane part was investigated by sequence comparisons and domain 
prediction algorithms. The catalytic domain (domain C, residues 250-408) and an 
adjacent domain (domain B: residues 150-250) was defined by sequence similarity to 
other LdtMt2 homologs in Mtb and Corynebacteria genomes (Figure 8&11A, paper I). 
We have predicted an additional domain (domain A, residues 34-150) based on 
domain-border analysis (http://www.tuat.ac.jp/~domserv/cgi-bin/DLP-SVM.cgi; Ebina 
et al. 2009) and secondary-structure prediction using JPred (Cole et al. 2008). The N-
terminal starting point of this domain was suggested by the predicted lipoprotein-
attachment site (position 35) (Rahman et al. 2008) or the start of the predicted 
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secondary-structure domain element at position 55. The collective results from the 
bioinformatics analysis for the periplasmic part of LdtMt2 defined three domains: two 
smaller domains A (residues 34/55-146) and B (residues 149-250) and a catalytic 
domain (C, residues 240-408) belonging to the EYY-fold family (Figure 8&11, 
Bielnicki et al. 2006). Based on the above analysis three constructs were investigated: a 
full-length periplasmic construct (residues 34-408), the AB module (residues 55-250) 
and the BC module (residues 149-408). These were expressed in E. coli and purified to 
homogeneity. All these constructs are in a monomeric state in solution according to 
size-exclusion chromatography results. Crystallization trials of the full-length construct 
did not result in crystal formation, however crystallization screening of the AB and BC-
domain resulted in well-diffracting crystals. 
 
Figure 11. Domain Organization and the X-ray Structure of LdtMt2. (A) Domain arrangement 
of LdtMt2 indicating the A, B, C domain with residues involved. The predicted trans-membrane 
(TM) region, the two immunoglobulin-like (Ig) domains A and B, the catalytic transpeptidase 
domain (C) and the C-terminal extension (W3) are illustrated. (B) Cartoon representation of 
the AB (PDB: 4HU2) module and BC (PDB: 4HUC) module in cartoon representation, colors 
as in panel-A.  
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The crystal structure of LdtMt2 was solved in two fragments comprising the AB and 
the BC domains. The structure of the BC module (PDB: 4HUC) was solved to 1.86 Å 
using Se-SAD phasing. Domain B unexpectedly revealed an immunoglobulin-like 
(Ig) fold, while domain C comprising the catalytic center belongs to the 
ErfK/YbiS/YbnG fold family. The structure of the AB-module (PDB: 4HU2) was 
solved by molecular replacement to 1.45 Å, using the B-module from the BC 
structure as search model. Despite the low sequence similarity (12%) the A domain 
reveals an Ig-like fold very similar to the B domain. The combination of both 
structures provides a view on the full-length periplasmic three-domain LdtMt2 protein 
(residues 55–408), which is in contrast to the two-domain model of LdtMt2 proposed 
involving only one Ig-like domain (domain B) by an earlier publication Erdemli et al. 
2012.  
The full periplasmic LdtMt2 structure is extending about 80-100 Å into the PG layer 
and defines the approximate distance at which the 3-3 cross-links are formed by this 
transpeptidase (Böth et al. 2013). Mycobacterial transpeptidases contain one or two 
Ig-like domains that likely play a spacer role for positioning the active site to the 
appropriate location where cross-link formation is performed (paper I, Böth et al. 
2013). The proposed domain arrangements for the short and longer Ldt homologues 
(Figure 8) were shortly after confirmed by the structures of the two domain LdtMt1 
(Correale et al. 2013) and the three-domain LdtMt2 (Li et al. 2013) and LdtMt5 (Basta et 
al. 2015).  
 
3.1.1 The Catalytic Domain of LdtMt2 
The crystal structure of the BC module was solved to 1.86 Å resolution by Se-SAD 
phasing from crystals of selenomethionine-substituted protein. Two polypeptide chains 
(residues 149–408) are defined in the asymmetric unit. The refined model contains also 
480 water molecules and 12 acetate ions, where two of the acetate ions are situated in 
the active site of domain C. Each polypeptide chain contains a bound metal-ion, which 
based on electron density, typical metal-ligand distances and coordination sphere was 
modeled as Na
+
 ion.  
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Structural comparison of domain C using the DALI algorithm (Holm & Rosenström 
2010) identified the transpeptidase domain of related proteins from Enterococcus 
faecium (PDB: 1ZAT, Biarotte-Sorin et al. 2006, Z-score of 19.3 and a C r.m.s.d of 
1.9 Å for 120 residue-long alignment) and a homologue in B. subtilis (PDB: 1Y7M, 
Bielnicki et al. 2006, Z-score of 17.7 and C r.m.s.d. of 1.6 Å for 109 residue-long 
alignment). The key residues of the catalytic site, Cys354 and His336, correspond to 
Cys442 and His421 in the E. faecium homologue. In LdtMt2 the active site is located 
under -hairpin lid (residues 298–324), which limits the access to the active site (Figure 
11B&12). The -hairpin lid is not present in the B. subtilis protein and part of the lid is 
disordered in the X-ray structure of the E. faecium homologue.  
 
 
Figure 12. The Active Site of LdtMt2. The -hairpin lid (residues 298-324, light brown) 
presents large hydrophobic residues (Tyr298, Tyr308 and Tyr318, orange sticks) and 
together with residues close to the active site entrance (Tyr330, Phe334 and Trp340, orange 
sticks) they are expected to regulate active site accessibility. The active site residues Cys354 
(green stick), His336 and His352 are highlighted in pink and blue, respectively.  
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In the LdtMt2 lid, large hydrophobic residues (Tyr298, Tyr308 and Tyr318) and the 
residues surrounding the entrance to the active site (Tyr330, Phe334 and Trp340) 
contribute to closure of the active site and exclusion of solvent, which might be 
important during catalysis (Figure 12). At the C-terminal end an extension comprising 
residues 382-408 (W3, Figure 11) can be found in LdtMt2. The W3 extension runs along 
the domain C and forms contacts with domain B stabilizing the relative orientation of 
domains B and C (Figure 11). In the W3 extension a pattern of tryptophan residues 
(Trp394, Trp398 and Trp401 in LdtMt2), present in LdtMt5 (Rv0483) as well forms 
stacking interactions at the domain interface.  
 
3.1.2 The AB-module as a Spacer in LdtMt2 
The structure of the AB module including A and B domains (57-250) was solved to 
1.45 Å resolution by molecular replacement using the B domain from the BC module 
structure (residues 149–250) as search model. The two domains appear in a V-shaped 
arrangement; each of them is built up by a -sandwich of two antiparallel -sheets 
(Figure 13). Both domains belong to the c-type Ig-fold, with strand orders a–b–e–d 
and c–f–g in the two antiparallel-sheets (Figure 13A, Bork et al. 1994).  
Comparison of the two domains A and B structures (sequence identity 12%) results in 
a C r.m.s.d. of 2.7 Å over 85 aligned residues (Figure 13B). The major differences 
between the two structures are an additional short -helix (residues 180–187 in 
domain B, between -strands 2 and 3) and the loop connecting 6 and 7, which is 
longer domain B (Figure 13B). The size of the A and B domain interface (350 Å
2
), 
the short linker (Ala149-His150) and the fact that B factors of the linker residues are 
in the range 18–22 Å2, comparable to the remaining part of the structure, suggests that 
the linker is not flexible, i.e. the V-shaped arrangement appears rather rigid (Figure 
11C). Superposition of the B domain from the AB and BC module shows high 
similarity over the full-length sequence (r.m.s.d. of 0.4 Å over 101 residues). The 
relative orientation of these domains retains this arrangement in the three-domain 
structure (Li et al. 2013).  
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Figure 13. The Ig-like Domains A and B of LdtMt2. (A) Domain topology diagram of domain 
A (red) and domain B (blue). (B) Superposition of the Cα-trace of domain A (red) and B 
(blue). The major differences, the short -helix (residues 180-187) inserted between 2 and 
3 and a longer loop connecting 6 and 7 are indicated with arrows on domain B. (C) The 
comparison of domain A and the Ig-like domains from other polysaccharide specific enzyme 
(endo--1,4-mannanase from C. fimi, PDB: 2X2Y) reveals the conserved residues shown as 
sticks (yellow) in domain A (red cartoon).  
 
Structural homologs of the two Ig-like domains using the DALI server were identified 
in Pseudomonas syringae (a periplasmic copper-resistance protein, PDB entry 2C9R, 
Zhang et al. 2006, Z-score of 10.2 and C r.m.s.d. of 2.4 Å), Halothermothrix orenii 
(N-terminal domain of amylase, PDB: 3BC9, Tan et al. 2008) and a similar domain of 
the endo--1, 4-mannanase from Cellulomonas fimi (PDB: 2X2Y, Hekmat et al., 
2010) with similar Z-scores (6.0–10.1) and r.m.s.d. values (C 2.6–3.1 Å). 
Additionally, the cell-wall-located S-layer protein from Geobacillus 
stearothermophilus (PDB: 2RA1, Pavkov et al. 2008) shows reasonable Z-score of 
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7.8 and a C r.m.s.d. value of 3.2 Å. Interestingly the non-catalytic Ig-like domains of 
the amylase from H. orenii have been shown to mediate enzyme activity within the 
high-molecular-weight (HMW) substrate (Tan et al. 2008). 
Similar sequences are present in enzymes processing high-molecular-weight 
polysaccharides. The domains of the mannanase in C. fimi (sequence identity 18.5%) 
and a glucodextranase from Arthrobacter globiformis (sequence identity 15.2%) 
could potentially be relevant for LdtMt2, as the substrate is a modified oligosaccharide 
chain. The conserved residues in domain A and the Ig-like domain from mannanase and 
glucodextranase contain a set of conserved Thr residues exposed on -sheet surface 
(Figure 13C).  
 
3.1.3 The Periplasmic LdtMt2 
The superposition of the B-domains in the AB and BC module structures, allows 
modeling the three-domain periplasmic LdtMt2 structure (Figure 14). This model is in 
good agreement with the three-domain structure solved later (PDB: 3VYN, Li et al. 
2013) indicated by the structural superimposition using DALI light server (Hasegawa & 
Holm 2009) resulting in a C r.m.s.d. value of 0.8 Å over 347 aligned residues. The 
three-domain LdtMt2 protein extends about 80-100 Å (including sequence 34-54) from 
the inner membrane. Compared to the other four LdtMt homologs in Mtb H37Rv 
genome there are variations in sequence length and predicted domains (Figure 8&14). 
The candidates Rv0116c (LdtMt1 with 45% sequence identity) and Rv1433 (LdtMt3 with 
38% sequence identity) also encode for a trans-membrane domain but the extra-
membrane sequence is one domain shorter (Figure 8A). The homologs Rv0483 (LdtMt5, 
35% identity) and Rv0192 (LdtMt4, 18% identity) were likely to contain three domains. 
The five Ldt homologs in Mtb therefore can be grouped into transpeptidases with one or 
two Ig-like domains positioning the catalytic center at different levels/height in the PG 
layer. Such an arrangement of the PG-production line (transpeptidases) supports the 
parallel multi-layered PG model (see chapter 1.4.3.3) within the mycobacterial cell 
wall. The Ig-like domains seem to act as spacer units and define the distance of catalytic 
action from the membrane. It appears that the 3-3 cross-link formation can occur at two 
levels carried out by long (Rv2518c, Rv0483 and Rv0192) and short (Rv0116c and 
Rv1433) transpeptidase variants (Figure 8B&14).  
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Figure 14. The Model of the Periplasmic LdtMt2. Superposition of domain B common in 
structure AB and BC results in the full-length LdtMt2 model. The catalytic center is placed at a 
maximal distance of 80–100 Å from the inner membrane. The structure of LdtMt1 (PDB: 
4JMN, to the right) is shown as an example for the mycobacterial two-domain (short) Ldt. 
The differences in the placement of the active sites suggest that the formation of 3-3 cross-
links may happen at two different levels within the peptidoglycan of Mtb.  
 
3.1.4 Covalent Adduct Formation with -lactam Antibiotics 
The inhibitory action of -lactam antibiotics is based on the formation of a covalent 
complex between the transpeptidase active site and the antibiotic. The active site serine 
residues in D,D-transpeptidases are the primary targets but the cysteine residues in L,D-
transpeptidases in B. subtilis (Lecoq et al. 2012) and the LdtMt2 (Rv0116c, Dubée et al. 
2012) were also shown to be targeted by -lactams. Covalent adduct formation could be 
observed with the BC module and the ABC construct (residues 34-408) of LdtMt2 with 
imipinem (299.3 Da, cabapenem) and ampicillin (349.4 Da, penam class) using ESI-
MS (paper I, Böth et al. 2013). The observed covalent mass differences correspond to 
the exact mass of the respective antibiotic. Together with the observation from 
imipinem and meropenem binding to LdtMt2 using ITC (Erdemli et al. 2012) and the 
crystal structures of meropenem-bound LdtMt2 (Li et al. 2013, Kim et al. 2013) the data 
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indicates that LdtMt2 is targeted by various -lactam antibiotics. However, a systematic 
analysis is necessary to identify the best candidates. LdtMt2 is one of the few validated 
targets in Mtb (Gupta at al. 2010) and as a periplasmic (extracellular) target presents 
high potential for future TB-therapy. 
 
3.2 PAPER II: BINDING AND PROCESSING OF -LACTAM ANTIBIOTICS 
BY THE TRANSPEPTIDASE LDTMT2 FROM MYCOBACTERIUM 
TUBERCULOSIS 
The use of -lactam antibiotics represents a novel way of anti-TB therapy (Rullas et al. 
2015, Hoagland et al. 2016). The L,D-transpeptidases were shown to bind -lactams, 
specifically carbapenems, resulting in a covalent modification of the active site cysteine 
by forming an acyl-enzyme adduct in the process referred to as acylation. We 
investigated a cohort of 16 -lactam antibiotics, from the penem, penam and 
carbapenem group, and characterized their action of inhibition by kinetics, mass 
spectrometry and X-ray crystallography on the essential LdtMt2 transpeptidase. Most 
compounds from the carbapenems class showed fast acylation kinetics but faropenem, a 
penem-type antibiotic, outperforms these by a 2–3 fold faster rate in adduct formation. 
Mass spectrometry results indicated that carbapenems antibiotics might undergo 
decarboxylation. Faropenem is also decomposing after the acylation step resulting in a 
87 Da -OH-butyryl adduct bound at the active site cysteine. The co-crystal structure of 
LdtMt2 with this faropenem fragment bound was solved to 1.54 Å resolution, and shows 
that the protein completely shields the cysteine-adduct from the solvent. The complex 
representing the inactivated state of the enzyme shows high stability in biochemical 
assays. 
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Figure 15. The 3-3 cross-link (DAP-DAP, dashed line) formation catalyzed by LdtMt2. 
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3.2.1 Adduct Formation at the Active Site Cys354 by -lactams 
The mechanism of peptide cross-link formation by Ldts includes a covalent intermediate 
formed between the donor peptide and the active site cysteine. This reaction intermediate is 
resolved by the amino group of the acceptor peptide (Figure 15). The action of -lactams 
relays on mimicking the donor peptide substrate hence, covalent binding of -lactam 
antibiotics starts with the nucleophilic attack of the catalytic Cys354 on the carbonyl carbon 
of the lactam ring leading to an enzyme-acyl adduct formation. This way the mechanism of 
action is similar to the inhibition of D,D-transpeptidases. The LdtMt2 construct used, namely 
the BC module (residues 149-408, Figure 11), contains a single cysteine residue, located in 
the active site. This opens the possibility to follow the acylation reaction by monitoring the 
covalent modification of Cys354 using dithio-nitrobenzoate (DTNB) spectrophotometrically 
at 412nm (Figure 16A).  
The fraction of free cysteine was monitored after exposure to -lactams (7 min) by DTNB-
derivatization and reactivity of the compounds, seven penam (PA), two penem (PE), six 
carbapenems (CA) and one cephem (CE), was ranked (Figure 16B). Fast Cys354 
modification was observed for the carbapenems tepipenem (TEBI), meropenem (MERO), 
ertapenem (ERTA), doripenem (DORI) and biapenem (BIA), for the two penem-type 
antibiotics faropenem (FARO) and faropenem daloxate (FAROdal) and three of the penams 
6-amino penicillanic acid (APA), piperacillin (PIP) and penicillin-G (PEN) (Figure 16B). The 
kinetic constants of the acylation reaction was measured and compared for the selected 
compounds, revealing that faropenem outperforms all other tested -lactams (Figure 16C).  
Electrospray ionization mass spectrometric (ESI-MS) analysis was used to confirm complex 
formation between the LdtMt2 and the selected -lactam compounds. Covalent complex 
formation with the expected m/z value (unmodified adduct mass) was detected as the main 
peak with thio-nitrobenzoate (TNB), tebipenem (TEBI), biapenem (BIA), carbenicillin 
(CAR) and piperacillin (PIP).  
The carbapenems MERO, ERTA and DORI adducts were detected with the expected 
unmodified masses however a peak corresponding to a 40–47 Da smaller mass were also 
detected (Figure 17). The mass difference could result from a decarboxylation reaction (44 
Da) on the -lactam ring, which has been observed in previous studies (Brown et al. 1996) 
and is in accordance with the error of the method (3–4 Da) in the mass-range monitored (30 
kDa). The faropenem derived adduct was detected as a 87 Da fragment, and indicated the 
decomposition of the bound antibiotic after the acylation step.  
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Figure 16. Investigation of -lactam Binding Based on Enzyme-acyl Formation at the LdtMt2 Active 
Site. (A) The presence of free Cys354 was monitored by 5,5’-dithio-bis-2-nitrobenzoic acid (DTNB) 
which leads to the formation of a cysteine-TNB adduct. A stoichiometric amount of TNB is released 
that can be followed spectrophotometrically at 412 nm. Enzyme-antibiotic adduct formation blocks 
the active site cysteine residue leading to a proportionally decreased spectrophotometric signal. (B) 
The comparison of the 16 different -lactam compounds (abbreviated names are used) regarding 
their reactivity in the acylation reaction. The LdtMt2 BC-module was exposed to 1 mM of antibiotic 
for 7 min followed by DTNB derivatization. Ranking of the compounds was possible based on 
comparison in acylation kinetics. (C) The acylation rate constants (kobs) at 50 M antibiotic 
concentration are shown for the six fastest -lactam compounds. The faropenem (FARO)-driven 
reaction is about 2–3 times faster than the carbapenems (ERTA, MERO, DORI), 7 times faster than 
piperacillin (PIP) and 17 times faster than 6-aminopenicillanicacid (APA). Error bars indicate the 
standard deviation for three independent measurements. (D) The adduct formation with faropenem 
and the adduct stability monitored in the presence of 2 mM acyl acceptor meso-DAP investigated by 
DTNB derivatization. Fast modification of the enzyme sulfhydryl group can be observed with 
FARO (black) and in the presence of meso-DAP (grey), and no difference in the adduct stability is 
observed. As a reference the reaction of the native protein (black dashed line) and the protein in 
presence of meso-DAP (grey dashed line) are given. 
 
The structure of this enzyme-adduct was investigated (Figure 18D) and the faropenem 
derived fragment was identified as a -OH-butyryl adduct (87 Da) bound at the active site 
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cysteine. The adduct resembles to the acyl-enzyme reaction intermediate formed during the 
catalytic cycle (Figure 15), hence the question arises if the acceptor peptide may react with 
this adduct releasing it, and consequently the unmodified enzyme. Therefore, the preformed 
adduct was challenged by potential acceptor substrates (L-alanine, L-lysine, L-
aminopimelate, D-aminopimelate) and the likely natural acceptor substrate meso-DAP, and 
the adduct stability was monitored by DTNB or by mass-spectrometry but no release of the 
free cysteine was observed. We also monitored the formation and stability of the adduct in 
the presence of the likely natural acceptor substrate meso-DAP, however neither the acylation 
kinetics nor the adduct stability was affected (Figure 16D). Consequently, faropenem was 
identified as the most efficient in binding kinetics, and the resulting adduct that represents the 
inactivated form of LdtMt2 shows a long-term stability.  
 
Figure 17. Representative Selection of-lactam Driven Adduct Formation on the LdtMt2 
Investigated by Mass Spectrometry. (Upper panel) Compounds selected come from the penem 
(PE), carbapenems (CA) and penam (PA) group. (Lower panel) Chemical structures are presented 
of the selected -lactam antibiotics and modifications by the LdtMt2 are highlighted in bold dashed 
lines and crosses. 
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3.2.2 Structures of Covalent Adducts at the LdtMt2 Active Site 
As part of the assay validation BC-module of LdtMt2 was crystallized with the bound TNB 
adduct. The 1.55 Å resolution structure clearly shows the TNB-adduct covalently bound to 
the Cys354 in the active site in both chains of the asymmetric unit. The catalytic site lays on a 
-sheet platform covered by a -hairpin loop called the lid (residues 300-323) adapting to 
ligand-dependent changes exposing or covering the active site (Figure 18A).  
 
Figure 18. Structures of LdtMt2 and Covalent Adducts Formed at the Cys354. (A) The C backbone 
trace representation of the apo-LdtMt2 (blue, 4HUC), in complex with the FARO-derived adduct 
(green, 5LBG), the LdtMt2-meropenem complex (orange, 4GSU) and the TNB-adduct (red, 5LB1) 
are superimposed to highlight the lid mobility. The Pro315 residue within the -hairpin loop is 
represented as stick model as a reference point. (B) The LdtMt2-TNB adduct structure in surface 
representation. The lid (residues 303-323, dark red) above the TNB adduct (stick model) within the 
active site is in open conformation. (C) Surface representation of the LdtMt2 with the faropenem-
derived adduct (light blue, stick model) in the active site. The lid is in a closed conformation 
comparable to the apo-LdtMt2 structure. (D) Active site map (stick model) of the LdtMt2 structure with 
the -OH-butyryl adduct (light blue) bound to Cys354 (yellow) within the active site cleft (residues 
as green sticks). The 2Fo-Fc electron density map contoured at 1σ is depicted as a grey mesh. 
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When the TNB adduct is bound, the lid is moved out with a displacement at the tip (Pro315) 
of 12.0 Å compared to the ligand free LdtMt2 structure (PDB: 4HUC, Figure 18A&B). The 
accessible surface area (ASA) for the Cys354-linked sulfur atom is 4.7 Å
2
.  
The faropenem derived adduct detected earlier by mass spectrometry (Figure 17) was 
captured in the crystals of LdtMt2 by soaking the crystals in 4mM faropenem. The 1.54 Å 
resolution crystal structure shows additional density covalently linked to the Cys354 in one of 
the polypeptide chains of the asymmetric unit. The size and shape corresponds to the -OH-
butyryl (87 Da) fragment observed in mass spectrometry and was modeled with satisfying 
refinement parameters. The lid is in a closed conformation comparable to the ligand free 
structure. Compared to the TNB adduct the FARO-derived adduct seems to be inaccessible 
with an ASA of 0.1 Å
2 
for the carbon atom of the carbonyl group that is in connection with 
Cys354. This is in line with the high stability of the -OH-butyryl adduct observed in 
biochemical assays (Figure 16D). As this adduct represents the inactivated state of the target 
protein, the above structure is an important piece of information in establishing the 
mechanism of action. 
 
3.2.3 Faropenem as the Most Efficient -lactam Targeting Mtb 
Faropenem was shown to be the most efficient -lactam killing Mtb in culture and inside 
macrophages (Dhar et al. 2015). This work gives insights to the mechanism of action of this 
-lactam compound on a validated target in Mtb and establishes some relevant points that 
may reveal the reason behind its success. The fast kinetics in inactivation of LdtMt2 and the 
high stability of the formed adduct that is protected by the enzyme are these relevant points. 
The same adducts formed by faropenem in targeting LdtMt1 and LdtMt2 were observed by 
other scientists, and the first steps of designing improved -lactam antibiotics based on these 
results have been taken (Kumar et al. 2017). 
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3.3 PAPER III: RIPD (RV1566C) FROM MYCOBACTERIUM TUBERCULOSIS: 
ADAPTATION OF AN NLPC/P60 DOMAIN TO A NON-CATALYTIC 
PEPTIDOGLYCAN-BINDING FUNCTION 
RipD (Rv1566c) from Mtb is, like RipA and RipB, a member of the enzyme family carrying 
an NlpC/P60 domain. However, alterations in the NlpC/P60 catalytic triad and a peculiar C-
terminal penta-peptide repeat extension distinguish RipD from the other previously 
characterized members of this enzyme family. A bioinformatics analysis revealed that RipD 
homologs containing these specific features occur in 11 mycobacterial genomes and similar 
penta-peptide repeats can be found in proteins from mycobacteriophage and other bacterial 
species with periplasmic localization. In contrast to RipA or RipB, RipD does not show PG 
hydrolase activity, which is in agreement with the residue alteration within the active site. 
However, PG binding of the NlpC/P60 core is retained, presenting the first non-catalytic 
NlpC/P60 protein with PG-binding function. CD-spectroscopy indicated the C-terminal 
repeat sequence is most likely a random coil in solution, a common feature of protein repeats. 
The unstructured character is also in agreement with the crystallographic analysis based on 
the 1.17 Å crystal structure carrying two penta-peptide repeat units. 
 
3.3.1 Structure of the Non-catalytic NlpC/P60 Hydrolase RipD (1566c) and 
RipDR2 
The RipD full-length protein consists of 230 amino acids encoding for a short N-terminal 
signal sequence (residue 1-30), a NlpC/P60 core domain, sharing about 50% sequence 
similarity with RipA and RipB, followed by a 61 residue C-terminal penta-peptide 
(PVQQAn) repeat sequence (Figure 10A&19A). Three protein constructs were produced in E. 
coli; a full-length RipD (residues 38–230, lacking signal sequence), a RipD-core (residues 
38-169, NlpC/P60 domain) and the RipDR2 (residues 38-182, NlpC/P60 domain plus 
P
173
VQQA-PVQPA
182
) including two penta-peptide repeat units (Figure 19A).  
The crystal structure of the RipD-core was determined by molecular replacement using the 
structure of the homologous protein from Mycobacterium avium (PDB: 3GT2) to 1.56 Å 
resolution. The structure of the core domain reflects an NlpC/P60 fold built up by five 
antiparallel -sheets and three-helices (Figure 19B). Superimposition of the RipD-core with 
structures of the NlpC/P60 domain of RipA and RipB results in an r.m.s.d. of 0.8 Å and 0.9 Å 
(over 130 C atoms) respectively. The RipD-core contains a PG-binding groove also present 
in the catalytically active homologues RipA and RipB (Böth et al. 2011, Figure 19C&D). The 
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main difference is that in the RipD-active site the cysteine and histidine residues are replaced 
by an alanine and serine, respectively (Figure 19D). Two acetate ions are bound within the 
groove, one in the center of the groove and another at the funnel entry (Figure 19D).  
 
Figure 19. RipD, a Catalytically Inactive Member of the NlpC/P60 Family. (A) Domain 
organization of RipD (Rv1566c) in Mtb and crystal structure of the RipD-core domain. The 
transmembrane region (TM) the core domain (NlpC/P60 domain) and the repeat sequence (residues 
169-230) in C-terminal position indicating the sequence of the repeat unit PVQQA. (B) The 1.56 Å 
resolution crystal structure of the RipD-core is presented (cartoon) built by a five-stranded 
antiparallel -sheets (red) and three -helices (yellow). (C) The peptide binding groove of RipD is 
superimposed with the catalytic active site of RipA. Residues forming the groove are represented as 
orange sticks for RipD and black sticks for RipA. Active site residues of RipA (grey sticks) and the 
corresponding amino acids in RipD (gold sticks) are highlighted. The polypeptide chain of the 
RipD-core (red cartoon) is presented. (D) Surface representation of the RipD-core domain to 
illustrate the peptide binding groove. The two acetate ions bound at the proteins surface are shown as 
yellow sticks. Alterations in the catalytic triad (A83, S132, E144) are shaded in beige and 
surrounding residues Trp59, Gln131 and Asp146 are highlighted as a reference points.   
 
The crystal structure of the RipD construct including two penta-peptide repeat units, RipDR2, 
was solved to 1.17 Å (Figure 20A). The electron density map allowed modeling of the core 
domain and the second repeat segment (residues P
178
VQPA
182
). Eight residues connecting the 
modeled repeat were disordered in the crystal. The PVQPA-repeat is bound in an extended 
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conformation at the interface of the symmetry related molecule (Figure 20A&B). The 
interaction at the interface is based on three hydrogen bonds and hydrophobic interactions 
(Figure 20B). The solution state of the RipD constructs used is monomeric according to size-
exclusion chromatography.  
 
3.3.2 The Penta-peptide Repeat  
The CD spectroscopy of the full-length RipD (residues 38-230) compared to the RipD-core 
domain (residues 38-169) demonstrates that the C-terminal tail adds an increased amount of 
random coiled regions, suggesting that the C-terminal repeat sequence does not adopt a 
specific secondary structure in solution, which is common for peptide repeat sequences.  
 
Table 3. RipD-like Proteins and Their Repeat Sequences in Mycobacterial Homologs. 
 
 
The RipD-like proteins can be found in 21 mycobacterial genomes and closely related species 
(e.g. Segniliparus rotundus), however RipD variants containing a PVQQA-type repeat 
sequence can only be found in a few mycobacterial species (Table 3). Similar peptide repeat 
sequences can be also found in other cell wall or periplasmic proteins e.g. in the 
Thiorhodococcus drewsii flagellar assembly protein FliH (UniProt ID G2E335; PXRQS8), 
Yersinia pseudotuberculosis haem exporter protein D (UniProt ID: Q668U1; PXQQX2 and 
PLHQX5) and the mycobacteriophage Pixie gp99 protein (UniProt ID: G1D508; PVQXX6) 
(Pope et al. 2011).  
 
Species (strain) Functional annotation
UniProt 
ID
Length 
(aa)
Repeat 
character 
N/L
Mycobacterium tuberculosis  (H37Rv) Invasion-associated O06624 230 10/5
Mycobacterium tuberculosis  (H37Ra)* Putative invasion protein A5U2S3 230 10/5
Mycobacterium bovis (BCG and AF2122/97) Putative invasion protein Q7VEY5 230 10/5
Mycobacterium ulcerans  (Agy99) Invasion protein A0PNZ9 259 16/5
Mycobacterium marinum  (ATCC BAA-535) Invasion protein B2HQ87 259 16/5
Mycobacterium avium  (k10) Hypothetical protein Q740S0 316 19/5 and 3/4
Mycobacterium avium  (104) NlpC/P60 protein A0QHK2 289 21/5 and 3/4 
Mycobacterium leprae  (TN) Secreted P60 protein Q9CC67 212 1/5
aa, amino acid; L, length of one repeat unit; N, number of repeats.
*Other M. tuberculosis strains: RGTB327, RGTB423, F11, CDC1551, Haarlem (draft) and strain C.
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Figure 20. (A) The penta-peptide repeat unit resolved in the RipDR2 crystal structure, PVQPA 
(green sticks), forms intermolecular contacts with a symmetry-related molecule in the crystal. (B) 
The PVQPA-repeat interactions at the intermolecular interface within the crystal lattice. Hydrogen 
bonds are illustrated with dashed lines, distances indicated.  
 
3.3.3 The Biochemical Properties of RipD  
The enzyme assay based on o-phthalaldehyde (o-PA) derivatization established for RipA and 
RipB (Böth et al. 2011) was used to detect peptidase activity with the dipeptide iE-DAP and 
the tripeptide tri-DAP as substrates using the catalytic RipAc domain as a positive control. 
According the expectations, the RipD-core domain did not show peptidase activity on the 
substrates tested. The RipD-core domain shows alterations at the corresponding residues 
where the cysteine is replaced by alanine (Ala83) and the histidine by a serine (Ser132) 
explaining the lack of peptidase activity (Figure 19D). The structures of the RipD, RipA and 
RipB PG binding grooves however are very similar and suggest PG binding for all three 
enzymes. 
To investigate a potential RipD PG binding activity we used PG from B. subtilis in a PG-
binding assay since the peptide stem has an identical peptide composition as PG from Mtb. 
Lysozyme and BSA were used as positive and negative controls, respectively. The RipD-core 
showed binding to high-molecular-weight (HMW)-PG demonstrating binding ability. The 
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presence of the C-terminal penta-peptide repeat however significantly lowered the binding to 
HMW-PG. Therefore we used mycobacterial cell wall extract (CWCx), including PG and 
arabinogalactan, to examine whether the full-length RipD is capable of binding other cell 
wall components. The RipD-core and the full-length RipD showed similar behavior in 
binding to CWCx as to HMW-PG and the presence of the C-terminal repeat seems to 
interfere with RipD-core PG-binding. Based on the ability of RipD to bind PG, we suggested 
for this non-catalytic variant a role in cell wall stabilization, serving as a shield to protect the 
peptide stems from cleavage by other hydrolases. 
 
3.4 PAPER IV (MANUSCRIPT IN PREPARATION): THE STRUCTURE OF THE 
N-TERMINAL MODULE OF THE CELL WALL HYDROLASE RIPA AND ITS 
ROLE IN REGULATING CATALYTIC ACTIVITY 
RipA is the mycobacterial NlpC/P60 hydrolase that has been most thoroughly investigated. 
The PG degrading activity based on the NlpC/P60 domain is potentially harmful therefore 
regulatory control is important. The N-terminal domain of RipA has been proposed to play an 
inhibitory role by blocking the C-terminal catalytic domain (Ruggerio et al. 2010, Botella et 
al. 2017). Active site accessibility is however not limited by the presence of the N-terminal 
domain, but by the lid-module of the inter-domain linker, that is situated in the PG binding 
groove of the catalytic domain. The N-terminal domain structure was solved to 2.25 Å 
resolution by Se-SAD phasing revealing an all-α-fold with two long antiparallel α-helices. 
Dimerization of this domain was observed in size exclusion chromatography and in SAXS 
experiments. Using SAXS data the periplasmic two-domain RipA structure was investigated 
and modeled presenting a rigid hairpin-like module and the catalytic domain connected by 
flexible linker (24 residues). This linker limits the movement of the catalytic domain and 
allows for a defined range of catalytic action and PG degradation. 
 
3.4.1 The Inter-Domain Linker Regulates Active Site Accessibility in RipA 
The RipA polypeptide chain contains an N-terminal signal sequence (TM, residues 1-39) 
predicted by the SignalP server (Petersen et al. 2011). The whole periplasmic RipA protein 
(RipApp, residues 39-472) contains a single cysteine residue, the catalytic Cys383, situated 
in the NlpC/P60 domain (Figure 21A). This fortunate condition gives the possibility to 
monitor active site accessibility using the sulfhydryl-specific DTNB derivatization assay 
(Figure 21B). We monitored the cysteine accessibility in RipApp, the catalytic domain 
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RipAc including a lid-module (X), the catalytic domain without the lid-module (RipActr) 
and a Cys383Ala mutant of RipActr, denoted as RipActr(C383A) (Figure 21B). The 
catalytic Cys383 was not exposed in the two-domain construct RipApp (residues 39-472) 
and not in the RipAc construct either. Cys383 only becomes accessible when the lid-
module (X) is not present indicating that it is the lid-module of the inter-domain linker 
(residues 260-321) and not the N-terminal domain, which regulate the active site 
accessibility. This implies also that the N-terminal domain may have another function. 
 
Figure 21. (A) The domain structure of RipA and the constructs used in the study are shown with the 
residue range indicated by horizontal bars with respect to the domain structure. The catalytic Cys383 
in the active site is highlighted in red, the lid-module (X) connecting the catalytic and N-terminal 
domain is coloured in orange. (B) The RipA active site accessibility is monitored at 412nm using 
DTNB derivatization of the catalytic Cys383 present in construct RipApp, RipAc and RipActr. The 
construct with the Cys383 mutated to alanine RipActr(C383A), was used as negative control. The 
columns represent the average of three independent measurements and standard deviation is indicated 
with error bars. 
 
3.4.2 Characterization and Structure of the N-terminal Domain of RipA: 
RipAn 
The N-terminal domain of RipA (RipAn, residues 39-255) was investigated by circular 
dichroism (CD) spectroscopy indicating an all -protein (minima at 222 and 208 nm and 
maximum at 202 nm). Analytical size exclusion chromatography (SEC) indicated the 
formation of dimers in solution. The catalytic module RipAc (residues 260-472) is a 
monomer in solution based on SEC, while the two-domain construct RipApp (residues 39-
472) representing the periplasmic RipA protein eluted in a single peak suggesting a size in 
between monomer and dimer (RipApp MW of 46 kDa).  
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The 2.25 Å resolution structure of RipAn was determined by Se-SAD phasing. It reveals an 
all-α-fold in agreement with the CD-spectroscopy data. The asymmetric unit contains a 
single polypeptide chain folded in two long helices with 92 (helix α1: D40-S131) and 103 
(helix α2: P138-E240) residues (Figure 22A). The two helices are connected by a 6-residue 
long loop (132-YLSASS-137).  
 
Figure 22. The Crystal Structure of the N-terminal Domain from RipA: RipAn. (A) Cartoon of RipAn 
presenting an all -fold with two long -helices (helix 1and helix 2) in rainbow color scheme. N- 
and C-termini are indicated. (B) Surface exposed conserved residues highlighted in red are grouped 
into three regions, region-1 and region-3 involve both helices, and region-2 only contains residues 
from helix α1. (C) PcsB (PDB: 4CGK) from S. pneumoniae is a peptidoglycan hydrolase involved in 
cell separation consisting of an N-terminal domain (black) and an NlpC/P60 domain (pink). 
Superimposition of RipAn (rainbow) and PcsB based on the helical domains is presented. 
 
Sequence alignments with RipA homologues from mycobacterial and Rhodococcus 
genomes (Figure 22B) indicate 42% sequence identity in the area of this two-helix module. 
Several of the residues are responsible for connecting the two α-helices, and are not surface 
exposed. The conserved sequences on the surface are grouped into three regions: region-1 
and region-3 including regions in both helices, while region-2 contains residues from α1 
only (Figure 22B).  
Structural comparisons of RipAn with other proteins from the PDB using the DALI 
algorithm (Holm & Rosenström 2010) result in a list of α-helical proteins with the most 
significant hit being PcsB, a PG remodeling protein from S. pneumoniae (Figure 22C). 
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PcsB contains a helical N-terminal domain and an NlpC/P60-like catalytic module, thereby 
it is a functional analogue of RipA (Bartual et al. 2014). The structural comparison of the 
N-terminal domain results in 13% sequence identity (over 141 residues) with Cα r.m.s.d. of 
3.4 Å and Z score of 6.3. 
 
3.4.3 Solution Structures from SAXS 
Small-angle X-ray scattering (SAXS) was used to investigate the solution state of RipAn 
(23.2 kDa), the N-terminal module of RipA, and RipApp (46.0 kDa), the two-domain 
construct representing the periplasmic segment. SAXS data was collected at pH 5.0-8.0 for 
RipAn and Guinier- and indirect Fourier transformation (IFT) analyses were performed to 
obtain information on oligomerization state of the proteins. At pH 5.0 RipAn is suggested a 
monomer as the dominant species with a small amount of dimers present. At pH 6.0-8.0 the 
calculated average molecular mass from IFT was 57.1 kDa yielding a monomer multiple of 
2.46. This points to the formation of dimers and perhaps coexistence of higher-order 
oligomers in all higher pH samples. Rigid-body refinement was performed using the online 
version of SASREF (Petoukhov et al. 2005, https://www.embl-hamburg.de/biosaxs/atsas-
online) with P2 symmetry constraints. Every run came out with very similar 3D structures 
with a dimer crossed about one quarter from the ends at an angle of ~120° (Figure 23A). 
The Aarhus in-house rigid-body refinement program, WLSQ_SYMXV1 was used along 
with SASREF on all samples to obtain complementary fits and resulting 3D structures 
almost identical (with SAXS resolution) and the crossed dimer motif is reproduced across 
runs, confirming again the robustness of the obtained structure. 
The scattering data from the RipApp sample at pH 8.0 was also evaluated by Guinier- and 
IFT analyses estimating the two-domain RipApp construct being a monomer with a small 
dimer fraction. The model of the complete two-domain construct was prepared from the X-
ray crystal structures of the RipAn domain (representing residues 40-240), the C-terminal 
NlpC/P60 domain (representing residues 265-472), and the 24 residue long inter-domain 
linker that was modeled using I-TASSER (Roy et al. 2010). No dimer structures consistent 
with the RipAn dimers could be fitted to the SAXS data. The best fits for the periplasmic 
segment of RipA were achieved with a monomer, where the linker and the catalytic domain 
flex back alongside the stalk but not collapsing onto it (Figure 23B).  
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Figure 23. Model of the Periplasmic RipA Based on X-ray Structures and SAXS Solution 
Structures. (A) SAXS solution structure of RipAn derived from SASREF rigid-body refinement of 
P2 dimers based on the RipAn crystal structure. (B) The SAXS solution structure of RipApp 
results from WLSQ_SYMXV1 rigid-body refinement of linked structures of RipAn-Linker-
RipAc. The model of the two domain structure is based on the crystal structure of RipAn (residues 
40-240) colored as rainbow, the inter-domain linker (residues 241- 264) in green and RipAc 
(residues 265-472) in red. (C) The PcsB structure (grey, PDB: 4CGK, left) and the two-domain 
structure of the RipA derived from SAXS data and the X-ray structures of the individual domains 
of RipA. Arrows are indicating the proposed range of movement of the catalytic domain and 
peptide bond cleavage within the thicker or thinner PG layer in S. pneumoniae and Mtb 
respectively. (D) A model for cell wall degradation by RipA is depicted suggesting a dimer at the 
septum of two daughter cells. 
 
3.4.4 Model of the Periplasmic RipA  
PcsB from S. pneumoniae was identified as the most relevant hit among structural 
homologues. It is also a functional analogue of RipA, displaying an NlpC/P60 domain, 
involved in cell division and contains a α-helical domain at N-terminal position (Bartual et 
al. 2014). Comparison of RipA and its functional analogue PcsB, reveals that PcsB has a 
third helical segment (47 residues) connecting the two helix module to the catalytic domain 
(Figure 23C). In RipA, the catalytic domain is connected to the two-helix module via a 
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shorter (24 residue) linker. The typical gram-positive PG layer is ranging from 200–400 Å 
(Giesbrecht et al. 1998, Bartual et al. 2014) while in Mtb the corresponding layer is thinner 
with 100–150 Å (Hett et al. 2008). Combinations of the catalytic domains with longer 
(PcsB) or shorter (RipA) structural spacers enable positioning of the catalytic hydrolase 
domain so it can work on thicker (S. pneumoniae) or thinner (Mtb) PG layer in the 
respective organism (Figure 23C, top). The observed dimerization of RipAn (SEC and 
SAXS) might position RipA proteins also as a dimer between the separating daughter cells 
combining a cleavage and tethering/locating function (Figure 23D, bottom). 
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4 CONCLUSIONS 
 
Paper I describes the crystal structure of the essential LdtMt2 transpeptidase in Mtb 
responsible for 3-3 cross-link formations. The periplasmic protein consists of three domains, 
two smaller Ig-like domains attached to a transpeptidase domain at the C-terminus. The full-
length structure was solved in two fragments and the combination of the two provides a view 
of the complete three-domain periplasmic LdtMt2 protein that extends about 80–100 Å from 
the inner membrane. The Ig-like domains might serve as spacer positioning the catalytic 
transpeptidase domain at the appropriate site within the PG layer, which defines the maximal 
distance for 3-3 cross-link formation by LdtMt2. The model also supports a complementary 
role for the longer three-domain and the shorter two-domain L,D-transpeptidases (e.g. LdtMt1) 
in carrying out the transpeptidation at two different levels in the multi-layered peptidoglycan. 
In paper I we also indicate that the LdtMt2 is targeted by -lactam antibiotics, suggesting a 
potential for the design of LdtMt2 specific inhibitors. 
In paper II a cohort of 16 -lactam antibiotics were investigated by binding kinetics, mass 
spectrometry, and X-ray crystallography to identify efficient compounds and study their 
action the LdtMt2. We gained insight into -lactam processing by the LdtMt2, where some 
carbapenem-type antibiotics seem to undergo decarboxylation and 6-aminopenicillanic acid 
can be coupled to a dimer by LdtMt2. We highlight faropenem, a penem-type -lactam, 
exhibiting the fastest binding kinetics and show that it is decomposed to a small 87 Da 
fragment that is stably bound to the active site of LdtMt2.The 1.54Å resolution crystal 
structure of this enzyme-adduct complex represents the inhibited state and has implications 
for the mechanism of action of faropenem. 
In paper III we show that RipD (Rv1566c) contains an NlpC/P60 domain that lacks catalytic 
activity, but retains PG binding in vitro. The RipD-core shows strong binding to high 
molecular weight PG and purified cell wall complex (CWCx) of M. smegmatis. RipD 
therefore represents the first example of a non-catalytic NlpC/P60 domain protein with PG-
binding function, an adaptation maybe specific for mycobacterium genus. RipD contains a 
61-residue-long unstructured C-terminal penta-peptide (PVQQA8) repeat sequence that 
interferes with PG binding in vitro. RipD most probably has a role in cell wall stabilization or 
in protecting the peptide linkages from hydrolysis by other catalytically active proteins. 
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Paper IV (Manuscript in progress) investigates the structure and role of the N-terminal 
domain of RipA. We show that the presence of the N-terminal domain does not affect 
active site accessibility, however the lid-module covering the peptide-binding groove of the 
catalytic domain does. The X-ray structure of the N-terminal domain reveals an all-α-fold 
with two long α-helices that form a dimer in solution. SAXS data in combination with X-
ray structures of both RipA domains were used to model the two-domain RipA consisting 
of a rigid hairpin-like module and the catalytic domain connected by a 24 residue long 
flexible linker. We propose that the linker limits the movement of the catalytic domain 
within the PG meshwork as part of the spatiotemporal control of peptidoglycan 
degradation. 
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